Page 1

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM MCPHS University | 2017–2018

enter


CONTENTS 4

About Sanofi Genzyme

5

Why Sanofi Genzyme

6

Letters from the Executive

8

Products and Pipelines

10

Fellowship Program Overview OUR FELLOWSHIP PROGRAMS

12 Global Commercial Strategy: Rare Diseases 14

Patients and science are at the center of everything we do, defining and uniting our efforts across rare diseases, multiple sclerosis, oncology, and immunology.

Global Commercial Strategy: Oncology

16 Global Pharmacovigilance 18 Global Medical Affairs: Rare Diseases 20

Global Medical Affairs/Scientific Communications: Oncology

22

Global Medical Affairs/Scientific Communications: Immunology

24

Global Medical Affairs/Scientific Communications: Multiple Sclerosis

26

US Medical Affairs: Multiple Sclerosis

28

US Medical Affairs/Medical Science Liaison: Rare Diseases

30

US Medical Affairs/Medical Science Liaison: Multiple Sclerosis

32 US Medical Managed Care 34 Global Regulatory Affairs 36 Global Regulatory Affairs: Chemistry, Manufacturing and Controls & Devices 38 MCPHS University 39 Fellowship Alumini 40

2

Application Process

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018


4

6

8

10

12

14

16

18

20

24

26

28

30

32

34

36

ABOUT SANOFI GENZYME

WHY SANOFI GENZYME

COMPANY OVERVIEW

Sanofi Genzyme’s culture is inspired – and built – by the dedication our employees demonstrate every day to remain science-driven and patient-focused.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, oncology and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

Our ambition is to be the industry leader in specialty care. We currently provide more than 20 treatments to patients globally, with many potential new therapies being studied in clinical trials and in Sanofi laboratories.

DEDICATION TO GLOBAL LEADERSHIP

LIVING THE CORPORATE VALUES

For Sanofi Genzyme, diversity means far more than

Sanofi Genzyme’s workplace culture is rooted in our corporate values: courage, respect, teamwork, and integrity. Guided by these principles, we’ve established an environment that nurtures autonomy, yet encourages teamwork, that inspires employees to think big while empowering them to take hands-on action.

being an equal opportunity employer. Of course, establishing policies and creating an environment that welcomes all types of people into the company is a high priority. But we are also, more broadly, defined by diversity: we serve patients in more than 100 countries worldwide with a wide range of medical needs. Thus, it’s critical to our business objectives that our employees understand and can address the

Our ambition is to be the industry leader in specialty care. We currently provide more than 20 treatments to patients globally, with many potential new therapies being studied in clinical trials and in Sanofi Genzyme Laboratories. 4

22

varying health-care and cultural needs of our many patient populations.

OPPORTUNITIES FOR GROWTH At Sanofi Genzyme, we have a strong record of promoting from within, and many of our top leaders have built a significant portion of their careers moving through the company. We’re deeply invested in the unique talents, skills, and interests of our staff, and we believe that any position at Sanofi Genzyme offers the opportunity for professional development. Often this happens organically: mentoring, coaching, and knowledge-sharing are a natural byproduct of our highly collaborative culture. Sanofi Genzyme’s operations depend on cross-functional teams managing various projects and initiatives, and this approach gives individuals the chance to get involved in areas beyond their own roles. It’s not unusual for employees to tap into expertise in another division in

Our employees benefit from the stability and resources of a large, established biotech, but the entrepreneurial spirit and “can-do” attitude of our earliest start-up days continue to infuse our culture. Every employee recognizes that somewhere, a patient is waiting for our help – lending a sense of purpose to our working environment.

MAKING AN IMPACT The number one reason our employees give for working at Sanofi Genzyme is the satisfaction of making a difference in the lives of patients. More than anything else, this passion for impact drives our staff to work with urgency and focus. For many, the commitment becomes a deeply personal one as they get to know patients – whose names and faces become the inspiration for every project, every deadline, every aspect of their working experience. Sanofi Genzyme offers every employee a path to succeed – and the resources, support, and inspiration to drive their professional development.

the company, or even another part of the world. Our emphasis on teamwork allows staff not only to learn from one another, but also discover new opportunities or roles that can expand their career horizons. Sanofi Genzyme executives and management are intimately involved in their divisions, and they lead by example, inspiring their teams to rise to challenges and reach for new heights.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


4

6

8

10

12

14

16

18

20

24

26

28

30

32

34

36

ABOUT SANOFI GENZYME

WHY SANOFI GENZYME

COMPANY OVERVIEW

Sanofi Genzyme’s culture is inspired – and built – by the dedication our employees demonstrate every day to remain science-driven and patient-focused.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, oncology and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

Our ambition is to be the industry leader in specialty care. We currently provide more than 20 treatments to patients globally, with many potential new therapies being studied in clinical trials and in Sanofi laboratories.

DEDICATION TO GLOBAL LEADERSHIP

LIVING THE CORPORATE VALUES

For Sanofi Genzyme, diversity means far more than

Sanofi Genzyme’s workplace culture is rooted in our corporate values: courage, respect, teamwork, and integrity. Guided by these principles, we’ve established an environment that nurtures autonomy, yet encourages teamwork, that inspires employees to think big while empowering them to take hands-on action.

being an equal opportunity employer. Of course, establishing policies and creating an environment that welcomes all types of people into the company is a high priority. But we are also, more broadly, defined by diversity: we serve patients in more than 100 countries worldwide with a wide range of medical needs. Thus, it’s critical to our business objectives that our employees understand and can address the

Our ambition is to be the industry leader in specialty care. We currently provide more than 20 treatments to patients globally, with many potential new therapies being studied in clinical trials and in Sanofi Genzyme Laboratories. 4

22

varying health-care and cultural needs of our many patient populations.

OPPORTUNITIES FOR GROWTH At Sanofi Genzyme, we have a strong record of promoting from within, and many of our top leaders have built a significant portion of their careers moving through the company. We’re deeply invested in the unique talents, skills, and interests of our staff, and we believe that any position at Sanofi Genzyme offers the opportunity for professional development. Often this happens organically: mentoring, coaching, and knowledge-sharing are a natural byproduct of our highly collaborative culture. Sanofi Genzyme’s operations depend on cross-functional teams managing various projects and initiatives, and this approach gives individuals the chance to get involved in areas beyond their own roles. It’s not unusual for employees to tap into expertise in another division in

Our employees benefit from the stability and resources of a large, established biotech, but the entrepreneurial spirit and “can-do” attitude of our earliest start-up days continue to infuse our culture. Every employee recognizes that somewhere, a patient is waiting for our help – lending a sense of purpose to our working environment.

MAKING AN IMPACT The number one reason our employees give for working at Sanofi Genzyme is the satisfaction of making a difference in the lives of patients. More than anything else, this passion for impact drives our staff to work with urgency and focus. For many, the commitment becomes a deeply personal one as they get to know patients – whose names and faces become the inspiration for every project, every deadline, every aspect of their working experience. Sanofi Genzyme offers every employee a path to succeed – and the resources, support, and inspiration to drive their professional development.

the company, or even another part of the world. Our emphasis on teamwork allows staff not only to learn from one another, but also discover new opportunities or roles that can expand their career horizons. Sanofi Genzyme executives and management are intimately involved in their divisions, and they lead by example, inspiring their teams to rise to challenges and reach for new heights.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

LETTERS FROM THE EXECUTIVE

Adrienne A. Aiello, PharmD, CMPP

Shariq Ali, PhD Dear Candidates,

Dear Candidates,

On behalf of the Sanofi Genzyme Executive Leadership Team, I’d like to thank you for your interest in the Sanofi

I am honored that you are considering Sanofi Genzyme/MCPHS University for your post-doctoral Fellowship and

Genzyme/MCPHS Biopharmaceutical Industry Fellowship Program. Sanofi Genzyme has been privileged to be

professional development. The PharmD Fellowship Program at Sanofi Genzyme has tremendous support from

able to expand our PharmD Fellowship program over the years and to consistently attract and retain successful

senior leadership and executives within the company. The organization is committed to providing PharmD Fellows

PharmD candidates.

with the experience needed to launch their industry career and excel in the pharmaceutical industry. We strive to

As pharmacists, there is a strong commitment to patient care. Patients and science are at the center of everything we do at Sanofi Genzyme, defining and uniting our efforts across rare diseases, multiple sclerosis, oncology, and immunology. We are always looking to find talented, motivated, and enthusiastic leaders to bring a new perspective and energy to our organization. With your help, Sanofi Genzyme can continue to provide hope to patients and their families around the world.

provide a well-rounded experience and to develop the next generation of leaders in the pharmaceutical industry. As a former PharmD Fellow, I understand the importance of choosing the right fit for your post-doctoral Fellowship. We are pleased to be able to offer Fellowships in diverse functions and therapeutic areas throughout Sanofi Genzyme. With 30 Fellows currently enrolled in the program, there is a built-in network of support and information at your fingertips. With the additional support of MCPHS and the MCPHS Fellowship Network, Sanofi Genzyme Fellows have consistently demonstrated individual success and enhanced leadership abilities throughout the 2 years of the program. Many of our Fellowships encourage rotations and cross-functional

Sincerely, Shariq Ali, PhD Executive Sponsor, Sanofi Genzyme PharmD Fellowship Senior Medical Director, Global Medical Affairs Rare Diseases

assignments to promote development and education about the ever-expanding options for PharmDs in the pharmaceutical and biotechnology industries. Sanofi Genzyme Fellows are highly valued members of the team and relied upon for business-critical projects throughout the organization. Our Fellows consistently demonstrate their value and continually impress senior leaders and executives with their dedication, knowledge, and irreplaceable perspective. With a 10-year trackrecord of training and developing the top PharmD talent in the industry, we are thrilled to be able to offer a unique experience at Sanofi Genzyme. The decision to pursue a post-doctoral Fellowship is a big step in your professional career and I truly appreciate your interest in the Sanofi Genzyme/MCPHS PharmD Fellowship programs. On behalf of the Sanofi Genzyme Executive Leadership Team and all the PharmD Fellows, I wish you much success in your future endeavors.

Best regards, Adrienne A. Aiello, PharmD, CMPP Fellowship Director, Sanofi Genzyme PharmD Fellowship Associate Director, Scientific Publications and Communications Rare Diseases

6

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

LETTERS FROM THE EXECUTIVE

Adrienne A. Aiello, PharmD, CMPP

Shariq Ali, PhD Dear Candidates,

Dear Candidates,

On behalf of the Sanofi Genzyme Executive Leadership Team, I’d like to thank you for your interest in the Sanofi

I am honored that you are considering Sanofi Genzyme/MCPHS University for your post-doctoral Fellowship and

Genzyme/MCPHS Biopharmaceutical Industry Fellowship Program. Sanofi Genzyme has been privileged to be

professional development. The PharmD Fellowship Program at Sanofi Genzyme has tremendous support from

able to expand our PharmD Fellowship program over the years and to consistently attract and retain successful

senior leadership and executives within the company. The organization is committed to providing PharmD Fellows

PharmD candidates.

with the experience needed to launch their industry career and excel in the pharmaceutical industry. We strive to

As pharmacists, there is a strong commitment to patient care. Patients and science are at the center of everything we do at Sanofi Genzyme, defining and uniting our efforts across rare diseases, multiple sclerosis, oncology, and immunology. We are always looking to find talented, motivated, and enthusiastic leaders to bring a new perspective and energy to our organization. With your help, Sanofi Genzyme can continue to provide hope to patients and their families around the world.

provide a well-rounded experience and to develop the next generation of leaders in the pharmaceutical industry. As a former PharmD Fellow, I understand the importance of choosing the right fit for your post-doctoral Fellowship. We are pleased to be able to offer Fellowships in diverse functions and therapeutic areas throughout Sanofi Genzyme. With 30 Fellows currently enrolled in the program, there is a built-in network of support and information at your fingertips. With the additional support of MCPHS and the MCPHS Fellowship Network, Sanofi Genzyme Fellows have consistently demonstrated individual success and enhanced leadership abilities throughout the 2 years of the program. Many of our Fellowships encourage rotations and cross-functional

Sincerely, Shariq Ali, PhD Executive Sponsor, Sanofi Genzyme PharmD Fellowship Senior Medical Director, Global Medical Affairs Rare Diseases

assignments to promote development and education about the ever-expanding options for PharmDs in the pharmaceutical and biotechnology industries. Sanofi Genzyme Fellows are highly valued members of the team and relied upon for business-critical projects throughout the organization. Our Fellows consistently demonstrate their value and continually impress senior leaders and executives with their dedication, knowledge, and irreplaceable perspective. With a 10-year trackrecord of training and developing the top PharmD talent in the industry, we are thrilled to be able to offer a unique experience at Sanofi Genzyme. The decision to pursue a post-doctoral Fellowship is a big step in your professional career and I truly appreciate your interest in the Sanofi Genzyme/MCPHS PharmD Fellowship programs. On behalf of the Sanofi Genzyme Executive Leadership Team and all the PharmD Fellows, I wish you much success in your future endeavors.

Best regards, Adrienne A. Aiello, PharmD, CMPP Fellowship Director, Sanofi Genzyme PharmD Fellowship Associate Director, Scientific Publications and Communications Rare Diseases

6

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


4

PRODUCTS AND PIPELINES Over the years, Sanofi Genzyme has focused on several medical areas, while remaining unified by a few key principles: addressing unmet medical needs, exploring innovative technologies and treatment approaches, and improving the lives of patients worldwide. RARE DISEASES We began by targeting treatments for lysosomal storage disorders – rare genetic conditions caused by enzyme deficiencies.

6

8

10

12

14

16

Technology

mAb

Dupilumab^ Nasal polyposis

mAb

Dupilumab^ Eosinophilic esophagitis

mAb

SAR156597 Systemic scleroderma

mAb

SAR156597 Idiopathic pulmonary fibrosis

mAb

Sarilumab^ Uveitis

mAb

mAb

Expanding our rare disease focus through research collaborations with companies such as Alnylam® Pharmaceuticals.

Isatuximab Multiple myeloma PD-1 Inhibitor^ 1st line non-small cell lung cancer

mAb

PD-1 Inhibitor^ Cutaneous squamous cell carcinoma

mAb

MULTIPLE SCLEROSIS

Isatuximab Acute lymphoblastic leukemia

mAb

Our focus on specialty care applies to the unique needs of the MS community.

PD-1 Inhibitor^ Advanced basal cell carcinoma

mAb

Two marketed therapies serving patients globally.

SAR566658 Solid tumors

mAb

Continued focus on innovation with research in key areas including targeted immunomodulation,

ONCOLOGY We have a strong heritage in oncology and are working to expand our contributions in the treatment of cancer. Ten marketed therapies treating several types of cancer globally. We have a significant presence in prostate cancer, providing important options to patients.

We are building a pipeline of potential treatments in immuno-oncology through our own research and partnerships.

Sanofi Genzyme is targeting unmet needs in immune diseases including rheumatoid arthritis, atopic dermatitis, asthma, and chronic sinusitis. Two marketed products and several candidates in earlier clinical programs.

Expanding our research focus through a collaboration with Regeneron.

Patisiran* Hereditary ATTR amyloidosis

RNAi

Fitusiran* Hemophilia

RNAi

NeoGAA Pompe disease, 2nd generation enzyme

protein-based therapy

Olipudase Alfa† Acid sphingomyelinase deficiency

protein-based therapy

venglustat Fabry disease

small molecule

venglustat Parkinson’s disease with a GBA mutation

small molecule

venglustat Gaucher type 3

small molecule

26

28

30

32

34

36

Phase I

Phase II

Phase III

MULTIPLE SCLEROSIS mAb

Items marked with ^ are being developed in collaboration with Regeneron and a * are being developed in collaboration with Alnylam® Pharmaceuticals. Items shown with a † denote a Phase II/III trial.

The agents mentioned here are investigational and have

therapeutic areas including genetic diseases such as

not been approved by the U.S. Food and Drug

cystic fibrosis, spinal muscular atrophy, and Leber’s

Administration (FDA) or any other regulatory agency

congenital amaurosis type 1. We have several programs

worldwide for the uses under investigation.

in multiple sclerosis with molecules addressing areas

In addition to the candidates in clinical development,

of unmet need, using approaches such as

we are conducting earlier stage research in a range of

8

24

RARE DISEASES

GLD52 (GZ402668) Multiple sclerosis

IMMUNOLOGY

22

IMMUNOLOGY Dupilumab^ Asthma

ONCOLOGY

neuroprotection, and remyelination; as well as efforts to address unmet needs in progressive multiple sclerosis.

20

With science and patients at the center of what we do, Sanofi Genzyme continues to focus on developing scientific approaches and novel therapies for complex and debilitating diseases.

Dedicated to improving patients’ access to early diagnosis and appropriate treatment.

Seven therapies for rare diseases including Fabry disease, Gaucher disease type 1, mucopolysaccharidosis I disease, Pompe disease, and certain types of thyroid cancer.

18

immunomodulation, neuroprotection, and remylination.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


4

PRODUCTS AND PIPELINES Over the years, Sanofi Genzyme has focused on several medical areas, while remaining unified by a few key principles: addressing unmet medical needs, exploring innovative technologies and treatment approaches, and improving the lives of patients worldwide. RARE DISEASES We began by targeting treatments for lysosomal storage disorders – rare genetic conditions caused by enzyme deficiencies.

6

8

10

12

14

16

Technology

mAb

Dupilumab^ Nasal polyposis

mAb

Dupilumab^ Eosinophilic esophagitis

mAb

SAR156597 Systemic scleroderma

mAb

SAR156597 Idiopathic pulmonary fibrosis

mAb

Sarilumab^ Uveitis

mAb

mAb

Expanding our rare disease focus through research collaborations with companies such as Alnylam® Pharmaceuticals.

Isatuximab Multiple myeloma PD-1 Inhibitor^ 1st line non-small cell lung cancer

mAb

PD-1 Inhibitor^ Cutaneous squamous cell carcinoma

mAb

MULTIPLE SCLEROSIS

Isatuximab Acute lymphoblastic leukemia

mAb

Our focus on specialty care applies to the unique needs of the MS community.

PD-1 Inhibitor^ Advanced basal cell carcinoma

mAb

Two marketed therapies serving patients globally.

SAR566658 Solid tumors

mAb

Continued focus on innovation with research in key areas including targeted immunomodulation,

ONCOLOGY We have a strong heritage in oncology and are working to expand our contributions in the treatment of cancer. Ten marketed therapies treating several types of cancer globally. We have a significant presence in prostate cancer, providing important options to patients.

We are building a pipeline of potential treatments in immuno-oncology through our own research and partnerships.

Sanofi Genzyme is targeting unmet needs in immune diseases including rheumatoid arthritis, atopic dermatitis, asthma, and chronic sinusitis. Two marketed products and several candidates in earlier clinical programs.

Expanding our research focus through a collaboration with Regeneron.

Patisiran* Hereditary ATTR amyloidosis

RNAi

Fitusiran* Hemophilia

RNAi

NeoGAA Pompe disease, 2nd generation enzyme

protein-based therapy

Olipudase Alfa† Acid sphingomyelinase deficiency

protein-based therapy

venglustat Fabry disease

small molecule

venglustat Parkinson’s disease with a GBA mutation

small molecule

venglustat Gaucher type 3

small molecule

26

28

30

32

34

36

Phase I

Phase II

Phase III

MULTIPLE SCLEROSIS mAb

Items marked with ^ are being developed in collaboration with Regeneron and a * are being developed in collaboration with Alnylam® Pharmaceuticals. Items shown with a † denote a Phase II/III trial.

The agents mentioned here are investigational and have

therapeutic areas including genetic diseases such as

not been approved by the U.S. Food and Drug

cystic fibrosis, spinal muscular atrophy, and Leber’s

Administration (FDA) or any other regulatory agency

congenital amaurosis type 1. We have several programs

worldwide for the uses under investigation.

in multiple sclerosis with molecules addressing areas

In addition to the candidates in clinical development,

of unmet need, using approaches such as

we are conducting earlier stage research in a range of

8

24

RARE DISEASES

GLD52 (GZ402668) Multiple sclerosis

IMMUNOLOGY

22

IMMUNOLOGY Dupilumab^ Asthma

ONCOLOGY

neuroprotection, and remyelination; as well as efforts to address unmet needs in progressive multiple sclerosis.

20

With science and patients at the center of what we do, Sanofi Genzyme continues to focus on developing scientific approaches and novel therapies for complex and debilitating diseases.

Dedicated to improving patients’ access to early diagnosis and appropriate treatment.

Seven therapies for rare diseases including Fabry disease, Gaucher disease type 1, mucopolysaccharidosis I disease, Pompe disease, and certain types of thyroid cancer.

18

immunomodulation, neuroprotection, and remylination.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

FELLOWSHIP PROGRAM OVERVIEW PROGRAM OVERVIEW

These 2-year Post-PharmD Industry Fellowships are intended to provide a comprehensive experience for Doctor of Pharmacy graduates within the biopharmaceutical industry. Currently, 13 programs across eight functional areas are offered: Pharmacovigilance, Regulatory Affairs, Regulatory Medical Writing, Medical Affairs, Medical Affairs/Scientific Communications, Medical Affairs/Medical Science Liaison, Medical Managed Care, and Commercial Strategy.

FELLOWSHIP DIRECTOR

Adrienne Aiello, PharmD, CMPP

CHIEF FELLOWS

Rebecca Call, PharmD, RPh

10

Bridget Cloonan, PharmD, RPh

COURAGE. RESPECT. TEAMWORK. INTEGRITY. These are the values that guide our work. They come alive in the stories we tell and motivate us to make a positive impact on the lives of patients worldwide. BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

FELLOWSHIP PROGRAM OVERVIEW PROGRAM OVERVIEW

These 2-year Post-PharmD Industry Fellowships are intended to provide a comprehensive experience for Doctor of Pharmacy graduates within the biopharmaceutical industry. Currently, 13 programs across eight functional areas are offered: Pharmacovigilance, Regulatory Affairs, Regulatory Medical Writing, Medical Affairs, Medical Affairs/Scientific Communications, Medical Affairs/Medical Science Liaison, Medical Managed Care, and Commercial Strategy.

FELLOWSHIP DIRECTOR

Adrienne Aiello, PharmD, CMPP

CHIEF FELLOWS

Rebecca Call, PharmD, RPh

10

Bridget Cloonan, PharmD, RPh

COURAGE. RESPECT. TEAMWORK. INTEGRITY. These are the values that guide our work. They come alive in the stories we tell and motivate us to make a positive impact on the lives of patients worldwide. BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

GLOBAL COMMERCIAL STRATEGY: RARE DISEASES PROGRAM LEADS/PRECEPTORS

PROGRAM GOALS

To achieve a thorough understanding of marketing and commercial strategies within the Rare Diseases Business Unit, while working cross-functionally in a rotation-based experience. Upon completion of this program, Fellows will have the experience and tools necessary for a successful commercial strategy career within the pharmaceutical industry. PRIMARY OBJECTIVES

• Increase brand and disease state awareness through coordinated marketing opportunities at global conferences

• Provide commercial assessments regarding business development opportunities that may complement the Rare Diseases portfolio • Gain insight into the integral and strategic roles of various functions within the Rare Diseases Business Unit throughout a product’s lifecycle

12

Global Marketing Business Development Global Commercial Strategy Competitive Intelligence

Positions recruiting

E

C LE

TIVE ROTAT

IO

Field Sales Integrated Solutions New Products Planning Commercial Operations Patient Advocacy Medical Affairs

Dr. Zhao is a Global Product Manager within the Rare Pediatric Diseases Business Unit at Sanofi Genzyme, based in Cambridge, MA. In her current role, Dr. Zhao focuses on mucopolysaccharidosis I patients worldwide and mucopolysaccharidosis II patients in Asia, Africa, and Japan & Pacific regions. Prior to joining Sanofi Genzyme, Dr. Zhao received a PharmD from the University of Michigan College of Pharmacy in Ann Arbor, MI. Following graduation, she completed a 2-year postPharmD Fellowship in Global Medical Affairs with Sanofi Oncology and served as Chief Fellow of the Sanofi Genzyme – MCPHS University Biopharmaceutical Fellowship Program from 2014–2015.

2

Market Research

S

• Compile and disseminate competitive intelligence insights across the global, regional, and country brand teams

NS

N

• Identify data gaps and develop appropriate solutions via the coordination of global market research activities

E ROTATIO

First-Year Fellow

Second-Year Fellow

Parth Savalia PharmD, MSc St. John’s University

Jennifer Baird, PharmD University of Pittsburgh

I found the Global Commercial Strategy Fellowship at Sanofi Genzyme to be a very unique opportunity in the pharmaceutical industry. I chose this Fellowship because of Sanofi Genzyme’s global impact in the underserved rare disease space. In this fast-paced environment, I am given countless opportunities to see the pharmaceutical industry from different focal points ranging from patient advocacy to global brand strategy. This Fellowship has offered me an environment to continually grow and develop project management, analytical, and communication skills both at the domestic and global levels.

• Collaborate on the development and refinement of product value messaging and disease-awareness materials to support strategic priorities globally and in the regions

R CO

Dr. Druetta is currently Head of Rare Pediatric Diseases & Endocrinology at Sanofi Genzyme, based in Cambridge, MA. Within the Global Rare Diseases Franchise, Dr. Druetta leads business strategy for mucopolysaccharidosis I worldwide, mucopolysaccharidosis II in South East Asia and South Africa, thyroid cancer, and additional rare disease business opportunities. She received her PhD in Biochemistry and Cellular Biology from the Université Lyon I – Claude Bernard in Lyon, France before entering the pharmaceutical industry. In 2000, Dr. Druetta joined Sanofi Genzyme and has held several commercial roles, including Latin America Marketing Director for Pompe disease, France Marketing & Sales Director for Pompe disease, and France Business Unit Director for Pompe and Fabry diseases.

Christina Zhao, PharmD

The variety and breadth of experiences gained within one short Fellowship year is unquantifiable. During my time in Global Commercial, I have had experience working across three global brand teams for established products within rare diseases. In these roles I have contributed to both the creation of strategy and tactical rollout around the globe. This unique Fellowship has taught me to thrive in a quick paced, rotationbased program while working both crossfunctionally and cross-culturally.

• Assist the cross-functional core team in the development of global brand strategy and support its implementation in regions worldwide

Laure Druetta, PhD

First-Year Fellow

Second-Year Fellow

Justin Worth, PharmD, MBA University of Connecticut

Sagar Shah, PharmD University of the Sciences

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

GLOBAL COMMERCIAL STRATEGY: RARE DISEASES PROGRAM LEADS/PRECEPTORS

PROGRAM GOALS

To achieve a thorough understanding of marketing and commercial strategies within the Rare Diseases Business Unit, while working cross-functionally in a rotation-based experience. Upon completion of this program, Fellows will have the experience and tools necessary for a successful commercial strategy career within the pharmaceutical industry. PRIMARY OBJECTIVES

• Increase brand and disease state awareness through coordinated marketing opportunities at global conferences

• Provide commercial assessments regarding business development opportunities that may complement the Rare Diseases portfolio • Gain insight into the integral and strategic roles of various functions within the Rare Diseases Business Unit throughout a product’s lifecycle

12

Global Marketing Business Development Global Commercial Strategy Competitive Intelligence

Positions recruiting

E

C LE

TIVE ROTAT

IO

Field Sales Integrated Solutions New Products Planning Commercial Operations Patient Advocacy Medical Affairs

Dr. Zhao is a Global Product Manager within the Rare Pediatric Diseases Business Unit at Sanofi Genzyme, based in Cambridge, MA. In her current role, Dr. Zhao focuses on mucopolysaccharidosis I patients worldwide and mucopolysaccharidosis II patients in Asia, Africa, and Japan & Pacific regions. Prior to joining Sanofi Genzyme, Dr. Zhao received a PharmD from the University of Michigan College of Pharmacy in Ann Arbor, MI. Following graduation, she completed a 2-year postPharmD Fellowship in Global Medical Affairs with Sanofi Oncology and served as Chief Fellow of the Sanofi Genzyme – MCPHS University Biopharmaceutical Fellowship Program from 2014–2015.

2

Market Research

S

• Compile and disseminate competitive intelligence insights across the global, regional, and country brand teams

NS

N

• Identify data gaps and develop appropriate solutions via the coordination of global market research activities

E ROTATIO

First-Year Fellow

Second-Year Fellow

Parth Savalia PharmD, MSc St. John’s University

Jennifer Baird, PharmD University of Pittsburgh

I found the Global Commercial Strategy Fellowship at Sanofi Genzyme to be a very unique opportunity in the pharmaceutical industry. I chose this Fellowship because of Sanofi Genzyme’s global impact in the underserved rare disease space. In this fast-paced environment, I am given countless opportunities to see the pharmaceutical industry from different focal points ranging from patient advocacy to global brand strategy. This Fellowship has offered me an environment to continually grow and develop project management, analytical, and communication skills both at the domestic and global levels.

• Collaborate on the development and refinement of product value messaging and disease-awareness materials to support strategic priorities globally and in the regions

R CO

Dr. Druetta is currently Head of Rare Pediatric Diseases & Endocrinology at Sanofi Genzyme, based in Cambridge, MA. Within the Global Rare Diseases Franchise, Dr. Druetta leads business strategy for mucopolysaccharidosis I worldwide, mucopolysaccharidosis II in South East Asia and South Africa, thyroid cancer, and additional rare disease business opportunities. She received her PhD in Biochemistry and Cellular Biology from the Université Lyon I – Claude Bernard in Lyon, France before entering the pharmaceutical industry. In 2000, Dr. Druetta joined Sanofi Genzyme and has held several commercial roles, including Latin America Marketing Director for Pompe disease, France Marketing & Sales Director for Pompe disease, and France Business Unit Director for Pompe and Fabry diseases.

Christina Zhao, PharmD

The variety and breadth of experiences gained within one short Fellowship year is unquantifiable. During my time in Global Commercial, I have had experience working across three global brand teams for established products within rare diseases. In these roles I have contributed to both the creation of strategy and tactical rollout around the globe. This unique Fellowship has taught me to thrive in a quick paced, rotationbased program while working both crossfunctionally and cross-culturally.

• Assist the cross-functional core team in the development of global brand strategy and support its implementation in regions worldwide

Laure Druetta, PhD

First-Year Fellow

Second-Year Fellow

Justin Worth, PharmD, MBA University of Connecticut

Sagar Shah, PharmD University of the Sciences

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

GLOBAL COMMERCIAL STRATEGY: ONCOLOGY PROGRAM LEADS/PRECEPTORS

PROGRAM GOALS

Provide hands-on experience in development and execution of commercial and marketing strategies with the understanding of the complexity of Oncology markets. PRIMARY OBJECTIVES • Understand the process of portfolio strategy development in different therapeutic areas in Oncology • Participate in the global brand plan development, long-range planning process, and all associated financial forecasting requirements • Contribute to brand positioning and message evolution and learn techniques for the continuous assessment and validation of brand differentiation • Gain insight into marketing research and analytical support to identify trends to support brand performance

R CO

E ROTATIO

NS

Global Marketing Market Research Market Access

Positions recruiting

1

Global Commercial Strategy

VE ROTA TI O N

New Products Planning

S

EL

TI EC

Zsuzsanna K. Devecseri, MD, MBA Dr. Devecseri is Associate Vice President and Global Prostate Cancer Program Lead. She oversees all aspects of the Prostate Cancer Program and focuses on ensuring ongoing regulatory approvals, market access and reimbursement in all major markets, optimized commercial value and return on investment, and the development and execution of the LCM plans. She earned her MD in Budapest, Hungary at the Semmelweis University of Medicine in 1992, her MBA degree at the Budapest University of Economics in 1998 and her Certificate in Health Economics and Outcome Research at University of Washington, Seattle, WA in 2013. She is also a certified medical insurance expert, marketing professional and professional business coach. After spending 6 years in clinical practice as a pediatrician, and 5 years in the health insurance and talent development business, she joined the pharmaceutical industry in 2004.

Andrew Hingle, PhD Dr. Andrew Hingle is a Director of Global Marketing. He oversees the development of the commercial strategy and operational planning implementation for oncology products as well as exploration of potential market opportunities. Andrew gained his PhD from University College London, UK in the field of Genetics and Biometry in 2001 before moving into the pharmaceutical industry focusing on genetic disease and in particular, cancer.

Commercial Operations Health Economics and Outcome Research Business Development

First-Year Fellow Zachary McCormack, PharmD Purdue University

14

able to lead key projects is only made possible by having a tremendously supportive senior management team that is dedicated to promoting my professional growth. Sanofi Genzyme has a long history of supporting their Fellows, which I find deeply humbling and has made me tremendously appreciative to be in the role I am.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

Image to go here

I was drawn to this Fellowship due to the truly unique opportunities an individual receives both in terms of mentorship as well as industry experience. Through my Fellowship, I have the ability to gain a comprehensive understanding of key commercial considerations by rotating to different areas and taking on meaningful roles in each position. Being

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

GLOBAL COMMERCIAL STRATEGY: ONCOLOGY PROGRAM LEADS/PRECEPTORS

PROGRAM GOALS

Provide hands-on experience in development and execution of commercial and marketing strategies with the understanding of the complexity of Oncology markets. PRIMARY OBJECTIVES • Understand the process of portfolio strategy development in different therapeutic areas in Oncology • Participate in the global brand plan development, long-range planning process, and all associated financial forecasting requirements • Contribute to brand positioning and message evolution and learn techniques for the continuous assessment and validation of brand differentiation • Gain insight into marketing research and analytical support to identify trends to support brand performance

R CO

E ROTATIO

NS

Global Marketing Market Research Market Access

Positions recruiting

1

Global Commercial Strategy

VE ROTA TI O N

New Products Planning

S

EL

TI EC

Zsuzsanna K. Devecseri, MD, MBA Dr. Devecseri is Associate Vice President and Global Prostate Cancer Program Lead. She oversees all aspects of the Prostate Cancer Program and focuses on ensuring ongoing regulatory approvals, market access and reimbursement in all major markets, optimized commercial value and return on investment, and the development and execution of the LCM plans. She earned her MD in Budapest, Hungary at the Semmelweis University of Medicine in 1992, her MBA degree at the Budapest University of Economics in 1998 and her Certificate in Health Economics and Outcome Research at University of Washington, Seattle, WA in 2013. She is also a certified medical insurance expert, marketing professional and professional business coach. After spending 6 years in clinical practice as a pediatrician, and 5 years in the health insurance and talent development business, she joined the pharmaceutical industry in 2004.

Andrew Hingle, PhD Dr. Andrew Hingle is a Director of Global Marketing. He oversees the development of the commercial strategy and operational planning implementation for oncology products as well as exploration of potential market opportunities. Andrew gained his PhD from University College London, UK in the field of Genetics and Biometry in 2001 before moving into the pharmaceutical industry focusing on genetic disease and in particular, cancer.

Commercial Operations Health Economics and Outcome Research Business Development

First-Year Fellow Zachary McCormack, PharmD Purdue University

14

able to lead key projects is only made possible by having a tremendously supportive senior management team that is dedicated to promoting my professional growth. Sanofi Genzyme has a long history of supporting their Fellows, which I find deeply humbling and has made me tremendously appreciative to be in the role I am.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

Image to go here

I was drawn to this Fellowship due to the truly unique opportunities an individual receives both in terms of mentorship as well as industry experience. Through my Fellowship, I have the ability to gain a comprehensive understanding of key commercial considerations by rotating to different areas and taking on meaningful roles in each position. Being

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

GLOBAL PHARMACOVIGILANCE PROGRAM LEADS/PRECEPTORS

The pharmaceutical industry is responsible for monitoring, assessing and communicating safety information throughout a product’s lifecycle. At Sanofi Genzyme, the Global Pharmacovigilance Department is responsible for these activities. The aim of pharmacovigilance is to enhance patient care and safety in relation to the use of pharmaceutical products by ensuring the benefit-risk profile remains favorable. Pharmacovigilance is a thriving field within the pharmaceutical industry and as regulations continue to expand and evolve the need for knowledgeable and qualified personnel increases. PRIMARY OBJECTIVES • Understand the mission of a pharmacovigilance department and the role of Global Pharmacovigilance in clinical development and product lifecycle management

• Enhance the ability to critically evaluate, interpret, synthesize, and present safety data in a clear and concise manner through written and verbal communication

• Become knowledgeable in current global pharmacovigilance regulations and guidelines, including those in the US and Europe

• Expand medical knowledge of products within various therapeutic areas (e.g. Rare Diseases, Multiple Sclerosis, Immunology, Vaccines, and Oncology)

• Develop the ability to think strategically with a global pharmacovigilance and regulatory perspective

Positions recruiting

1

Manfred Oster, MD Dr. Oster is Vice President and Head of Global Safety Sciences in Global Pharmacovigilance. Before joining the industry, he received an MD from the Johannes Gutenberg University of Mainz in Germany and completed Fellowships in Internal Medicine and Nephrology. He also holds a graduate degree in Epidemiology from the University of London. After joining the industry in Hoechst AG, Germany, he held positions of increasing responsibility in Pharmacovigilance and in the Chief Medical Office at Sanofi or predecessor companies. He is specifically interested in clinical development and has been closely involved in many regulatory submissions and interactions.

Dr. Szymaniak is currently a Pharmacovigilance Scientist supporting the Global Pharmacovigilance Immunology and Oncology teams and is based in Cambridge, MA. She received her PharmD from MCPHS University. Following graduation, she completed a 2-year Fellowship in Global Pharmacovigilance through MCPHS University and Sanofi Genzyme. During this time, she also obtained a Graduate Certificate in Regulatory Affairs from MCPHS University. As a graduate of the Global Pharmacovigilance Fellowship Program, Dr. Szymaniak utilizes the first-hand knowledge gained during the program to ensure Fellows are provided with the experiences and mentorship necessary to develop a successful career within the pharmaceutical industry.

First-Year Fellow

Second-Year Fellow

Hayk Krikorian, PharmD, RPh MCPHS University – Boston

Sarah McGill, PharmD, RPh MCPHS University – Boston

As a first-year Fellow in Global Pharmacovigilance, I am excited and humbled to be integrated into an experienced team that is heavily invested in the professional development of the Fellow. Access to strong academic mentors and a diverse and expansive network of Fellows, both at Sanofi Genzyme and through MCPHS University, are invaluable advantages unique to this Fellowship Program.

16

Kate Szymaniak, PharmD, RPh

Over the past year, I have been exposed to many unique opportunities to work on critical crossfunctional projects in multiple therapeutic areas. In addition to my core role, I have improved my skills in an academic setting as a course coordinator at MCPHS University. Having the mentorship of my Program Leads and preceptors has propelled my professional growth. This Fellowship has provided me with experiences and skills necessary to succeed and excel in my field.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

PROGRAM GOALS

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

GLOBAL PHARMACOVIGILANCE PROGRAM LEADS/PRECEPTORS

The pharmaceutical industry is responsible for monitoring, assessing and communicating safety information throughout a product’s lifecycle. At Sanofi Genzyme, the Global Pharmacovigilance Department is responsible for these activities. The aim of pharmacovigilance is to enhance patient care and safety in relation to the use of pharmaceutical products by ensuring the benefit-risk profile remains favorable. Pharmacovigilance is a thriving field within the pharmaceutical industry and as regulations continue to expand and evolve the need for knowledgeable and qualified personnel increases. PRIMARY OBJECTIVES • Understand the mission of a pharmacovigilance department and the role of Global Pharmacovigilance in clinical development and product lifecycle management

• Enhance the ability to critically evaluate, interpret, synthesize, and present safety data in a clear and concise manner through written and verbal communication

• Become knowledgeable in current global pharmacovigilance regulations and guidelines, including those in the US and Europe

• Expand medical knowledge of products within various therapeutic areas (e.g. Rare Diseases, Multiple Sclerosis, Immunology, Vaccines, and Oncology)

• Develop the ability to think strategically with a global pharmacovigilance and regulatory perspective

Positions recruiting

1

Manfred Oster, MD Dr. Oster is Vice President and Head of Global Safety Sciences in Global Pharmacovigilance. Before joining the industry, he received an MD from the Johannes Gutenberg University of Mainz in Germany and completed Fellowships in Internal Medicine and Nephrology. He also holds a graduate degree in Epidemiology from the University of London. After joining the industry in Hoechst AG, Germany, he held positions of increasing responsibility in Pharmacovigilance and in the Chief Medical Office at Sanofi or predecessor companies. He is specifically interested in clinical development and has been closely involved in many regulatory submissions and interactions.

Dr. Szymaniak is currently a Pharmacovigilance Scientist supporting the Global Pharmacovigilance Immunology and Oncology teams and is based in Cambridge, MA. She received her PharmD from MCPHS University. Following graduation, she completed a 2-year Fellowship in Global Pharmacovigilance through MCPHS University and Sanofi Genzyme. During this time, she also obtained a Graduate Certificate in Regulatory Affairs from MCPHS University. As a graduate of the Global Pharmacovigilance Fellowship Program, Dr. Szymaniak utilizes the first-hand knowledge gained during the program to ensure Fellows are provided with the experiences and mentorship necessary to develop a successful career within the pharmaceutical industry.

First-Year Fellow

Second-Year Fellow

Hayk Krikorian, PharmD, RPh MCPHS University – Boston

Sarah McGill, PharmD, RPh MCPHS University – Boston

As a first-year Fellow in Global Pharmacovigilance, I am excited and humbled to be integrated into an experienced team that is heavily invested in the professional development of the Fellow. Access to strong academic mentors and a diverse and expansive network of Fellows, both at Sanofi Genzyme and through MCPHS University, are invaluable advantages unique to this Fellowship Program.

16

Kate Szymaniak, PharmD, RPh

Over the past year, I have been exposed to many unique opportunities to work on critical crossfunctional projects in multiple therapeutic areas. In addition to my core role, I have improved my skills in an academic setting as a course coordinator at MCPHS University. Having the mentorship of my Program Leads and preceptors has propelled my professional growth. This Fellowship has provided me with experiences and skills necessary to succeed and excel in my field.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

PROGRAM GOALS

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

GLOBAL MEDICAL AFFAIRS: RARE DISEASES PROGRAM GOALS

PROGRAM LEADS/PRECEPTORS

To gain a thorough understanding of rare genetic conditions, approved treatments, and products in development while working cross-functionally as an integral member of the Global Medical Affairs team in a rotation-based experience. PRIMARY OBJECTIVES

• Review and provide constructive feedback on various medical educational and training documents.

Medical Education

Strategic Planning & Operations Medical Communications & Publications

Positions recruiting

2

Commercial/Marketing Clinical Development

EL

TI EC

Dr. Thibault is currently a Senior Manager, Medical Communications for Sanofi Genzyme Global Medical Affairs: Rare Diseases. In his current role, he is responsible for planning and executing the strategy and tactics for medical communications/education within Rare Neurology and Rare Pediatrics. He received his PharmD from MCPHS University in Worcester, MA in May 2015 and, following graduation, completed a 2-year Fellowship in Global Medical Affairs: Rare Diseases at Sanofi Genzyme. Dr. Thibault started in his current role in May 2017.

VE ROTA TI O

Medical Science Liaison Market Access/Patient Advocacy Competitive Intelligence Health Economics & Outcomes Research

S

• Identify, establish, and maintain collaborative relationships with key investigators and institutions that are strategic to product development and will increase the company’s visibility with industry leaders, while providing an avenue for clinical research that is consistent with the company’s objectives.

NS

N

• Serve as a core member of the Medical Affairs team to ensure that activities and initiatives are aligned with those of the commercial functions in a way that achieves collective goals while being in compliance with corporate and regulatory policies.

E ROTATIO

First-Year Fellow

Second-Year Fellow

Yestle Kim, PharmD Northeastern University

Audrey Hou, PharmD Rutgers University

In the Global Medical Affairs: Rare Diseases Fellowship, you get to truly learn what it means to transform a patient’s life. As a health-care professional, I want to continue to put patients first and this organization does nothing but just that. As a Fellow, there are endless opportunities to touch different areas within the industry – not only can you play an integral role in collaborating with various functional areas, but you can also take ownership of projects to make a meaningful impact in the medical society.

• Work with the Medical Affairs team, including, but not limited to: Medical Communications Leads, Medical Science Liaisons, Medical Directors, Medical Writers, and other relevant team members on the development and approval of core clinical material.

R CO

Dr. Aiello is currently the Associate Director of Publications for Sanofi Genzyme Global Medical Affairs: Rare Diseases, in Cambridge, MA. She received her PharmD from Massachusetts College of Pharmacy and Health Sciences University in Boston, MA. Following graduation, she completed a 2-year Rutgers Pharmaceutical Industry Fellowship in Medical Affairs at Bayer HealthCare Pharmaceuticals in the Neurology business unit. Dr. Aiello joined Sanofi Genzyme in 2012 and is currently leading publication initiatives for Pompe Disease and Rare Neurological Diseases. Adrienne took on the role of Director of the Sanofi Genzyme PharmD Fellowship in 2016. She is a member of ASHP and ISMPP.

Nathan Thibault, PharmD

The Global Medical Affairs: Rare Diseases Fellowship has supported my professional growth through cross-functional collaboration on impactful projects with an extensive support network of Preceptors, Fellows, and mentors. As a second-year Fellow, I work as a fully integrated member of the team and take ownership of projects. The flexibility of the program allows me to work with key business partners and gain exposure to other functional areas. The experiences and knowledge gained throughout this Fellowship will be valuable going forward.

First-Year Fellow Pallavi Jain, PharmD MCPHS University – Boston

18

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

• Attend medical/scientific meetings to ensure an in-depth understanding of cutting edge information that will help shape our publication and Investigator Sponsored Study strategies.

Adrienne A. Aiello, PharmD, CMPP

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

GLOBAL MEDICAL AFFAIRS: RARE DISEASES PROGRAM GOALS

PROGRAM LEADS/PRECEPTORS

To gain a thorough understanding of rare genetic conditions, approved treatments, and products in development while working cross-functionally as an integral member of the Global Medical Affairs team in a rotation-based experience. PRIMARY OBJECTIVES

• Review and provide constructive feedback on various medical educational and training documents.

Medical Education

Strategic Planning & Operations Medical Communications & Publications

Positions recruiting

2

Commercial/Marketing Clinical Development

EL

TI EC

Dr. Thibault is currently a Senior Manager, Medical Communications for Sanofi Genzyme Global Medical Affairs: Rare Diseases. In his current role, he is responsible for planning and executing the strategy and tactics for medical communications/education within Rare Neurology and Rare Pediatrics. He received his PharmD from MCPHS University in Worcester, MA in May 2015 and, following graduation, completed a 2-year Fellowship in Global Medical Affairs: Rare Diseases at Sanofi Genzyme. Dr. Thibault started in his current role in May 2017.

VE ROTA TI O

Medical Science Liaison Market Access/Patient Advocacy Competitive Intelligence Health Economics & Outcomes Research

S

• Identify, establish, and maintain collaborative relationships with key investigators and institutions that are strategic to product development and will increase the company’s visibility with industry leaders, while providing an avenue for clinical research that is consistent with the company’s objectives.

NS

N

• Serve as a core member of the Medical Affairs team to ensure that activities and initiatives are aligned with those of the commercial functions in a way that achieves collective goals while being in compliance with corporate and regulatory policies.

E ROTATIO

First-Year Fellow

Second-Year Fellow

Yestle Kim, PharmD Northeastern University

Audrey Hou, PharmD Rutgers University

In the Global Medical Affairs: Rare Diseases Fellowship, you get to truly learn what it means to transform a patient’s life. As a health-care professional, I want to continue to put patients first and this organization does nothing but just that. As a Fellow, there are endless opportunities to touch different areas within the industry – not only can you play an integral role in collaborating with various functional areas, but you can also take ownership of projects to make a meaningful impact in the medical society.

• Work with the Medical Affairs team, including, but not limited to: Medical Communications Leads, Medical Science Liaisons, Medical Directors, Medical Writers, and other relevant team members on the development and approval of core clinical material.

R CO

Dr. Aiello is currently the Associate Director of Publications for Sanofi Genzyme Global Medical Affairs: Rare Diseases, in Cambridge, MA. She received her PharmD from Massachusetts College of Pharmacy and Health Sciences University in Boston, MA. Following graduation, she completed a 2-year Rutgers Pharmaceutical Industry Fellowship in Medical Affairs at Bayer HealthCare Pharmaceuticals in the Neurology business unit. Dr. Aiello joined Sanofi Genzyme in 2012 and is currently leading publication initiatives for Pompe Disease and Rare Neurological Diseases. Adrienne took on the role of Director of the Sanofi Genzyme PharmD Fellowship in 2016. She is a member of ASHP and ISMPP.

Nathan Thibault, PharmD

The Global Medical Affairs: Rare Diseases Fellowship has supported my professional growth through cross-functional collaboration on impactful projects with an extensive support network of Preceptors, Fellows, and mentors. As a second-year Fellow, I work as a fully integrated member of the team and take ownership of projects. The flexibility of the program allows me to work with key business partners and gain exposure to other functional areas. The experiences and knowledge gained throughout this Fellowship will be valuable going forward.

First-Year Fellow Pallavi Jain, PharmD MCPHS University – Boston

18

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

• Attend medical/scientific meetings to ensure an in-depth understanding of cutting edge information that will help shape our publication and Investigator Sponsored Study strategies.

Adrienne A. Aiello, PharmD, CMPP

38

40


GLOBAL MEDICAL AFFAIRS/ SCIENTIFIC COMMUNICATIONS: ONCOLOGY

4

6

To gain an appreciation and understanding of the role of Scientific Communications and Medical Affairs within a leading BioPharma business, through broad hands-on experiences, dedicated mentorship, and longitudinal core responsibilities. PRIMARY OBJECTIVES

• Develop and execute on strategic publication plans, collaborating with key internal and external stakeholders and medical communications agencies providing writing, editorial and/or project management support in accordance with policies and International Committee of Medical Journal Editors (ICMJE) guidelines.

16

18

20

24

R CO

E ROTATIO

NS

Scientific Communications Strategy & Planning Medical Communications

Positions recruiting

Medical

E

1

C LE

TIVE ROTAT

Jill Ilsley, PhD

26

28

30

32

34

36

Dr. Ilsley is currently Senior Director, Head of Scientific Communications, for Immunology & Oncology, within Global Medical Affairs at Sanofi Genzyme. In this role, she leads a team of professionals overseeing scientific communications strategic planning and development of medical communications, publications, and medical education initiatives.

Dr. Michelini is currently the Director of Scientific Communications and Publications for Global Medical Affairs: Oncology. In this role she is responsible for the strategic development and execution of the publications plans for Oncology and provides support and guidance to the broader team on medical communications activities.

During her 12 years with Sanofi Genzyme, she has held various leadership roles in the US, Europe/International and Global Medical Affairs organizations and has mentored numerous graduate/undergraduate interns and PharmD Fellows. Dr. Ilsley holds a PhD in Molecular Medicine and a Master’s in Human Genetics, from the UConn Health Center, Farmington, CT, a Certification in BioPharma Business, and a Bachelor’s in Biochemistry from the University of New Hampshire, Durham, NH and has published in numerous peer-reviewed medical journals.

Dr. Michelini joined Sanofi Genzyme in 2017, bringing with her extensive experience in Oncology and Scientific Communications from a number of pharmaceutical and biotechnology companies. Prior to entering the pharmaceutical industry she was an Oncology Clinical Pharmacist at Methodist Hospital in Indiana. Dr. Michelini received her PharmD from the University of Michigan, Ann Arbor, MI and completed a Clinical Pharmacy residency at the University of Nebraska Medical Center, Omaha, NE.

IO

Medical Director

Commercial/Marketing Medical Science Liaison/ Field Medical Competitive Intelligence Clinical Study Operations Market Access

Teri Michelini, PharmD

Second-Year Fellow

Second-Year Fellow

Katherine Joseph, PharmD Touro College of Pharmacy

Nikita Mehta, PharmD Northeastern University

My Fellowship has provided many opportunities to work as an integral part of my team. Proactively participating in various activities within medical communications and publications, alongside excellent mentorship, makes this program the best place to advance my career.

20

22

S

• Work cross-functionally to ensure that activities and initiatives are strategically aligned and maintain the highest standards of compliance in accordance with corporate policies and all regulations.

14

N

• Understand the integral and strategic roles of various functional groups within Oncology and across Sanofi Genzyme through a product’s lifecycle.

12

As a second-year Fellow, I have become an essential part of my team and have established a presence in the company as a whole. As time has progressed, the knowledge I have has become deeper, the relationships I built have become stronger, and the contributions I have made have become more valuable. I look forward to continue to make my mark in the industry with this Fellowship.

• Identify, establish, and maintain collaborative relationships within the industry.

10

PROGRAM LEADS/PRECEPTORS

PROGRAM GOALS

• Serve as a core member of the Medical Affairs team and assist with the development and approval of integrated medical plans, scientific communications, and medical education programs.

8

First-Year Fellow

Second-Year Fellow

Rosemary Boshar, PharmD MCPHS University - Worcester

Mansi Jamindar, PharmD MCPHS University - Boston

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


GLOBAL MEDICAL AFFAIRS/ SCIENTIFIC COMMUNICATIONS: ONCOLOGY

4

6

To gain an appreciation and understanding of the role of Scientific Communications and Medical Affairs within a leading BioPharma business, through broad hands-on experiences, dedicated mentorship, and longitudinal core responsibilities. PRIMARY OBJECTIVES

• Develop and execute on strategic publication plans, collaborating with key internal and external stakeholders and medical communications agencies providing writing, editorial and/or project management support in accordance with policies and International Committee of Medical Journal Editors (ICMJE) guidelines.

16

18

20

24

R CO

E ROTATIO

NS

Scientific Communications Strategy & Planning Medical Communications

Positions recruiting

Medical

E

1

C LE

TIVE ROTAT

Jill Ilsley, PhD

26

28

30

32

34

36

Dr. Ilsley is currently Senior Director, Head of Scientific Communications, for Immunology & Oncology, within Global Medical Affairs at Sanofi Genzyme. In this role, she leads a team of professionals overseeing scientific communications strategic planning and development of medical communications, publications, and medical education initiatives.

Dr. Michelini is currently the Director of Scientific Communications and Publications for Global Medical Affairs: Oncology. In this role she is responsible for the strategic development and execution of the publications plans for Oncology and provides support and guidance to the broader team on medical communications activities.

During her 12 years with Sanofi Genzyme, she has held various leadership roles in the US, Europe/International and Global Medical Affairs organizations and has mentored numerous graduate/undergraduate interns and PharmD Fellows. Dr. Ilsley holds a PhD in Molecular Medicine and a Master’s in Human Genetics, from the UConn Health Center, Farmington, CT, a Certification in BioPharma Business, and a Bachelor’s in Biochemistry from the University of New Hampshire, Durham, NH and has published in numerous peer-reviewed medical journals.

Dr. Michelini joined Sanofi Genzyme in 2017, bringing with her extensive experience in Oncology and Scientific Communications from a number of pharmaceutical and biotechnology companies. Prior to entering the pharmaceutical industry she was an Oncology Clinical Pharmacist at Methodist Hospital in Indiana. Dr. Michelini received her PharmD from the University of Michigan, Ann Arbor, MI and completed a Clinical Pharmacy residency at the University of Nebraska Medical Center, Omaha, NE.

IO

Medical Director

Commercial/Marketing Medical Science Liaison/ Field Medical Competitive Intelligence Clinical Study Operations Market Access

Teri Michelini, PharmD

Second-Year Fellow

Second-Year Fellow

Katherine Joseph, PharmD Touro College of Pharmacy

Nikita Mehta, PharmD Northeastern University

My Fellowship has provided many opportunities to work as an integral part of my team. Proactively participating in various activities within medical communications and publications, alongside excellent mentorship, makes this program the best place to advance my career.

20

22

S

• Work cross-functionally to ensure that activities and initiatives are strategically aligned and maintain the highest standards of compliance in accordance with corporate policies and all regulations.

14

N

• Understand the integral and strategic roles of various functional groups within Oncology and across Sanofi Genzyme through a product’s lifecycle.

12

As a second-year Fellow, I have become an essential part of my team and have established a presence in the company as a whole. As time has progressed, the knowledge I have has become deeper, the relationships I built have become stronger, and the contributions I have made have become more valuable. I look forward to continue to make my mark in the industry with this Fellowship.

• Identify, establish, and maintain collaborative relationships within the industry.

10

PROGRAM LEADS/PRECEPTORS

PROGRAM GOALS

• Serve as a core member of the Medical Affairs team and assist with the development and approval of integrated medical plans, scientific communications, and medical education programs.

8

First-Year Fellow

Second-Year Fellow

Rosemary Boshar, PharmD MCPHS University - Worcester

Mansi Jamindar, PharmD MCPHS University - Boston

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


GLOBAL MEDICAL AFFAIRS/ SCIENTIFIC COMMUNICATIONS: IMMUNOLOGY

4

6

To gain an appreciation and understanding of the role of Scientific Communications and Medical Affairs within a leading BioPharma business, through broad hands-on experiences, dedicated mentorship, and longitudinal core responsibilities.

• Identify, establish, and maintain collaborative relationships within the industry.

14

16

18

20

24

26

28

30

32

34

36

R CO

E ROTATIO

Dr. Ilsley is currently Senior Director, Head of Scientific Communications, for Immunology & Oncology, within Global Medical Affairs at Sanofi Genzyme. In this role, she leads a team of professionals overseeing scientific communications strategic planning and development of medical communications, publications, and medical education initiatives.

NS

Scientific Communications Strategy & Planning Positions recruiting

Medical Communications

2

Medical Publications

TIVE ROTAT

During her 12 years with Sanofi Genzyme, she has held various leadership roles in the US, Europe/

International and Global Medical Affairs organizations and has mentored numerous graduate/undergraduate interns and PharmD Fellows. Dr. Ilsley holds a PhD in Molecular Medicine and a Master’s in Human Genetics, from the UConn Health Center, Farmington, CT, a Certification in BioPharma Business, and a Bachelor’s in Biochemistry from the University of New Hampshire, Durham, NH and has published in numerous peerreviewed medical journals.

IO

Medical Director

• Understand the integral and strategic roles of various functional groups within Immunology and across Sanofi Genzyme through a product’s lifecycle.

Medical Science Liaison/ Field Medical

• Work cross-functionally to ensure that activities and initiatives are strategically aligned and maintain the highest standards of compliance in accordance with corporate policies and all regulations.

Competitive Intelligence

S

E

C LE

Jill Ilsley, PhD

Commercial/Marketing Clinical Study Operations Market Access

First-Year Fellow

Second-Year Fellow

Cindy Chen, PharmD Rutgers University

Mansi Jamindar, PharmD MCPHS University - Boston

Professional development is a top priority throughout this Fellowship. From Day One, I was able to meet various mentors who provided great advice on how to effectively navigate through the program and industry as a whole. Fellows have the opportunity to gain hands-on experiences while being able to lead impactful projects. I am looking forward to building my skillset and the opportunity to work with supportive mentors who are passionate about helping patients worldwide.

22

22

N

• Develop and execute on strategic publication plans, collaborating with key internal and external stakeholders and medical communications agencies providing writing, editorial and/or project management support in accordance with policies and International Committee of Medical Journal Editors (ICMJE) guidelines.

12

The Fellowship has provided me with invaluable experience of being an integral member of a cross-functional team. The immunology component of my Fellowship has provided me with the incredible experience of working on a launch product, in which I have been able to play a major role in developing deliverables such as medical communications tools and scientific coverage at several pre- and post-launch congresses.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

• Serve as a core member of the Medical Affairs team and assist with the development and approval of integrated medical plans, scientific communications, and medical education programs.

10

PROGRAM LEAD/PRECEPTOR

PROGRAM GOALS

PRIMARY OBJECTIVES

8

38

40


GLOBAL MEDICAL AFFAIRS/ SCIENTIFIC COMMUNICATIONS: IMMUNOLOGY

4

6

To gain an appreciation and understanding of the role of Scientific Communications and Medical Affairs within a leading BioPharma business, through broad hands-on experiences, dedicated mentorship, and longitudinal core responsibilities.

• Identify, establish, and maintain collaborative relationships within the industry.

14

16

18

20

24

26

28

30

32

34

36

R CO

E ROTATIO

Dr. Ilsley is currently Senior Director, Head of Scientific Communications, for Immunology & Oncology, within Global Medical Affairs at Sanofi Genzyme. In this role, she leads a team of professionals overseeing scientific communications strategic planning and development of medical communications, publications, and medical education initiatives.

NS

Scientific Communications Strategy & Planning Positions recruiting

Medical Communications

2

Medical Publications

TIVE ROTAT

During her 12 years with Sanofi Genzyme, she has held various leadership roles in the US, Europe/

International and Global Medical Affairs organizations and has mentored numerous graduate/undergraduate interns and PharmD Fellows. Dr. Ilsley holds a PhD in Molecular Medicine and a Master’s in Human Genetics, from the UConn Health Center, Farmington, CT, a Certification in BioPharma Business, and a Bachelor’s in Biochemistry from the University of New Hampshire, Durham, NH and has published in numerous peerreviewed medical journals.

IO

Medical Director

• Understand the integral and strategic roles of various functional groups within Immunology and across Sanofi Genzyme through a product’s lifecycle.

Medical Science Liaison/ Field Medical

• Work cross-functionally to ensure that activities and initiatives are strategically aligned and maintain the highest standards of compliance in accordance with corporate policies and all regulations.

Competitive Intelligence

S

E

C LE

Jill Ilsley, PhD

Commercial/Marketing Clinical Study Operations Market Access

First-Year Fellow

Second-Year Fellow

Cindy Chen, PharmD Rutgers University

Mansi Jamindar, PharmD MCPHS University - Boston

Professional development is a top priority throughout this Fellowship. From Day One, I was able to meet various mentors who provided great advice on how to effectively navigate through the program and industry as a whole. Fellows have the opportunity to gain hands-on experiences while being able to lead impactful projects. I am looking forward to building my skillset and the opportunity to work with supportive mentors who are passionate about helping patients worldwide.

22

22

N

• Develop and execute on strategic publication plans, collaborating with key internal and external stakeholders and medical communications agencies providing writing, editorial and/or project management support in accordance with policies and International Committee of Medical Journal Editors (ICMJE) guidelines.

12

The Fellowship has provided me with invaluable experience of being an integral member of a cross-functional team. The immunology component of my Fellowship has provided me with the incredible experience of working on a launch product, in which I have been able to play a major role in developing deliverables such as medical communications tools and scientific coverage at several pre- and post-launch congresses.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

• Serve as a core member of the Medical Affairs team and assist with the development and approval of integrated medical plans, scientific communications, and medical education programs.

10

PROGRAM LEAD/PRECEPTOR

PROGRAM GOALS

PRIMARY OBJECTIVES

8

38

40


GLOBAL MEDICAL AFFAIRS/ SCIENTIFIC COMMUNICATIONS: MULTIPLE SCLEROSIS

4

PROGRAM GOALS

6

8

10

12

14

16

18

20

Steven Cavalier, MD Dr. Cavalier currently leads the Multiple Sclerosis Global Scientific Communication team at Sanofi Genzyme. He is a board-certified neurologist and practiced neurology with an emphasis on multiple sclerosis for 23 years. He entered the pharmaceutical industry in 2009. Dr. Cavalier is a graduate of Tulane University and Tulane Medical School, New Orleans, LA and holds a Master’s in Medical Management from the Marshall School of Business at University of Southern California, Los Angeles, CA.

PRIMARY OBJECTIVES

24

28

30

32

34

36

Medical Communications Scientific Publications

EL

E

Colin Mitchell, PhD Dr. Mitchell is currently an Associate Director on the Multiple Sclerosis Publications Team. Dr. Mitchell has supported the development and execution of publications and medical communications strategy for a variety of products over the past 12 years, previously at Biogen, Lilly, and Complete Healthcare Communications before joining Sanofi Genzyme. Dr. Mitchell has a PhD in Biopsychology and Behavioral Neuroscience from Rutgers University, New Brunswick, NJ and completed a postdoctoral Fellowship at the University of Chicago Department of Psychiatry and Behavioral Neuroscience, Chicago, IL.

NS

Positions recruiting

1

VE ROTA T CTI

IO

Medical Science Liaison Global Training Medical Managed Care Commercial Medical Director Competitive Intelligence

First-Year Fellow

Second-Year Fellow

Jordan Messer, PharmD UNC Eshelman School of Pharmacy

Jonathan Valenzano, PharmD Thomas Jefferson University

As a member of Sanofi Genzyme’s Global Medical Affairs team for our multiple sclerosis products, I have been given numerous opportunities to broaden my professional network on a global level and impact multiple sclerosis patients not only in the United States, but around the world. Everyone who I have collaborated with at the company is passionate about their work and takes a genuine interest in my past experiences and goals for my future.

• Identify, establish, and maintain collaborative relationships within the broader organization and industry.

E ROTATIO

S

• Serve as a core member of the Medical Affairs team and assist with the development and execution of integrated medical affairs plans.

R CO

N

• Become an integral member of the congress planning team to develop materials and publications to support key neurology and multiple sclerosis medical congresses such as the American Academy of Neurology, Consortium of Multiple Sclerosis Centers, European Academy of Neurology, and European Committee for Treatment and Research in Multiple Sclerosis.

26

The Fellowship Program continues to offer me many opportunities to get involved with high-level projects and immersive experiences. Recently, I have enjoyed doing elective rotations with the Medical Science Liaison field team and exploring other roles in the pharmaceutical industry. I value the mentorship I receive from my team and the strong Fellowship community we have at Sanofi Genzyme.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

• Contribute to the execution of the strategic medical communication tactics including scientific education and training materials, interactive digital materials and resources to support the field medical team.

24

PROGRAM LEADS/PRECEPTORS

To gain an understanding of the role of Medical Communications, Publications and Training within the Global Medical Affairs Multiple Sclerosis team, through broad hands-on experiences, dedicated mentorship, and longitudinal core responsibilities that will prepare the Fellow for a career in the pharmaceutical industry. The rotation schedule is flexible and designed to maximize opportunities for the Fellow to become a functional member of the team. We encourage elective rotations, participating in medical congresses and meetings, and getting involved early on in the Fellowship. • Develop and execute on strategic publication plans in accordance with policies and International Committee of Medical Journal Editors (ICMJE) guidelines, collaborating with key internal and external stakeholders and medical communications agencies providing writing, editorial and/or project management support.

22

38

40


GLOBAL MEDICAL AFFAIRS/ SCIENTIFIC COMMUNICATIONS: MULTIPLE SCLEROSIS

4

PROGRAM GOALS

6

8

10

12

14

16

18

20

Steven Cavalier, MD Dr. Cavalier currently leads the Multiple Sclerosis Global Scientific Communication team at Sanofi Genzyme. He is a board-certified neurologist and practiced neurology with an emphasis on multiple sclerosis for 23 years. He entered the pharmaceutical industry in 2009. Dr. Cavalier is a graduate of Tulane University and Tulane Medical School, New Orleans, LA and holds a Master’s in Medical Management from the Marshall School of Business at University of Southern California, Los Angeles, CA.

PRIMARY OBJECTIVES

24

28

30

32

34

36

Medical Communications Scientific Publications

EL

E

Colin Mitchell, PhD Dr. Mitchell is currently an Associate Director on the Multiple Sclerosis Publications Team. Dr. Mitchell has supported the development and execution of publications and medical communications strategy for a variety of products over the past 12 years, previously at Biogen, Lilly, and Complete Healthcare Communications before joining Sanofi Genzyme. Dr. Mitchell has a PhD in Biopsychology and Behavioral Neuroscience from Rutgers University, New Brunswick, NJ and completed a postdoctoral Fellowship at the University of Chicago Department of Psychiatry and Behavioral Neuroscience, Chicago, IL.

NS

Positions recruiting

1

VE ROTA T CTI

IO

Medical Science Liaison Global Training Medical Managed Care Commercial Medical Director Competitive Intelligence

First-Year Fellow

Second-Year Fellow

Jordan Messer, PharmD UNC Eshelman School of Pharmacy

Jonathan Valenzano, PharmD Thomas Jefferson University

As a member of Sanofi Genzyme’s Global Medical Affairs team for our multiple sclerosis products, I have been given numerous opportunities to broaden my professional network on a global level and impact multiple sclerosis patients not only in the United States, but around the world. Everyone who I have collaborated with at the company is passionate about their work and takes a genuine interest in my past experiences and goals for my future.

• Identify, establish, and maintain collaborative relationships within the broader organization and industry.

E ROTATIO

S

• Serve as a core member of the Medical Affairs team and assist with the development and execution of integrated medical affairs plans.

R CO

N

• Become an integral member of the congress planning team to develop materials and publications to support key neurology and multiple sclerosis medical congresses such as the American Academy of Neurology, Consortium of Multiple Sclerosis Centers, European Academy of Neurology, and European Committee for Treatment and Research in Multiple Sclerosis.

26

The Fellowship Program continues to offer me many opportunities to get involved with high-level projects and immersive experiences. Recently, I have enjoyed doing elective rotations with the Medical Science Liaison field team and exploring other roles in the pharmaceutical industry. I value the mentorship I receive from my team and the strong Fellowship community we have at Sanofi Genzyme.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

• Contribute to the execution of the strategic medical communication tactics including scientific education and training materials, interactive digital materials and resources to support the field medical team.

24

PROGRAM LEADS/PRECEPTORS

To gain an understanding of the role of Medical Communications, Publications and Training within the Global Medical Affairs Multiple Sclerosis team, through broad hands-on experiences, dedicated mentorship, and longitudinal core responsibilities that will prepare the Fellow for a career in the pharmaceutical industry. The rotation schedule is flexible and designed to maximize opportunities for the Fellow to become a functional member of the team. We encourage elective rotations, participating in medical congresses and meetings, and getting involved early on in the Fellowship. • Develop and execute on strategic publication plans in accordance with policies and International Committee of Medical Journal Editors (ICMJE) guidelines, collaborating with key internal and external stakeholders and medical communications agencies providing writing, editorial and/or project management support.

22

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

US MEDICAL AFFAIRS: MULTIPLE SCLEROSIS PROGRAM LEAD/PRECEPTOR

PROGRAM GOALS

To gain an appreciation and understanding of the roles and responsibilities of the Multiple Sclerosis Medical Affairs group, specifically the Medical Directors, and work cross-functionally across various functional teams as an essential member of the North American Medical Affairs organization, gaining a diverse range of experiences and deliverables.

Jeffrey M. Chavin, MD

PRIMARY OBJECTIVES

• Help to develop publication strategies of key scientific and/or commercial value through partnership with the Health Economics & Outcomes Research group, as well as the Medical Publication and Communication teams

NS

Medical Science Liaison Team

Positions recruiting

1

Medical Publications/ Communications Health Economics & Outcomes Research

EL

TI EC

VE ROTA TI O

S

• Collaborate with key internal and external stakeholders and scientific communications agencies on various project, scientific education, and training materials

Headquarters Medical Affairs

N

• D  evelop scientific and medical materials used throughout Medical Affairs and the Multiple Sclerosis Business Unit

E ROTATIO

Marketing Market Access Pharmacovigilance Clinical Development Patient Advocacy

26

First-Year Fellow

Second-Year Fellow

Raymond Doan, PharmD Northeastern University

Sibin Stephen, PharmD Rutgers University

Sanofi Genzyme offers the flexibility to rotate into various functional areas and opportunities to dive deep into meaningful projects. It is clear that the Fellows are valued members of any team here and are supported by brilliant Preceptors.

Something very apparent to me as a Fellow is the pride and sense of accomplishment that the Multiple Sclerosis medical team have in the work they produce here at Sanofi Genzyme. This Fellowship provides the opportunity to work under the direct tutelage of exceptional Medical Directors with a wide breadth of experiences.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

• Work closely with Headquarters Medical Affairs and the rest of the Medical Affairs team to communicate up-to-date scientific/medical information; attend scientific and medical congresses to better understand Medical Affairs’ role at these events

R CO

• Become an integral part of the Multiple Sclerosis Medical Director team in developing and executing medical brand strategies and tactics within the framework of the business unit

Dr. Chavin currently leads a Medical Affairs team at Sanofi Genzyme, in the Multiple Sclerosis Business Unit in Cambridge, MA. Dr. Chavin received his BS in Biology with Honors from Lafayette College, Easton, PA and received his MD degree from Temple University School of Medicine, Philadelphia, PA. Dr. Chavin completed his internship at Penn Presbyterian Medical Center, Philadelphia, PA and completed his Neurology Residency at Thomas Jefferson University Hospital. He also completed his Neuromuscular Medicine Fellowship at Tufts Medical Center, Boston, MA. Prior to joining Genzyme, Dr. Chavin held a faculty appointment as an Associate Professor of Neurology at Tufts Medical Center, Boston, MA where he was the Director of the Multiple Sclerosis Center.

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

US MEDICAL AFFAIRS: MULTIPLE SCLEROSIS PROGRAM LEAD/PRECEPTOR

PROGRAM GOALS

To gain an appreciation and understanding of the roles and responsibilities of the Multiple Sclerosis Medical Affairs group, specifically the Medical Directors, and work cross-functionally across various functional teams as an essential member of the North American Medical Affairs organization, gaining a diverse range of experiences and deliverables.

Jeffrey M. Chavin, MD

PRIMARY OBJECTIVES

• Help to develop publication strategies of key scientific and/or commercial value through partnership with the Health Economics & Outcomes Research group, as well as the Medical Publication and Communication teams

NS

Medical Science Liaison Team

Positions recruiting

1

Medical Publications/ Communications Health Economics & Outcomes Research

EL

TI EC

VE ROTA TI O

S

• Collaborate with key internal and external stakeholders and scientific communications agencies on various project, scientific education, and training materials

Headquarters Medical Affairs

N

• D  evelop scientific and medical materials used throughout Medical Affairs and the Multiple Sclerosis Business Unit

E ROTATIO

Marketing Market Access Pharmacovigilance Clinical Development Patient Advocacy

26

First-Year Fellow

Second-Year Fellow

Raymond Doan, PharmD Northeastern University

Sibin Stephen, PharmD Rutgers University

Sanofi Genzyme offers the flexibility to rotate into various functional areas and opportunities to dive deep into meaningful projects. It is clear that the Fellows are valued members of any team here and are supported by brilliant Preceptors.

Something very apparent to me as a Fellow is the pride and sense of accomplishment that the Multiple Sclerosis medical team have in the work they produce here at Sanofi Genzyme. This Fellowship provides the opportunity to work under the direct tutelage of exceptional Medical Directors with a wide breadth of experiences.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

• Work closely with Headquarters Medical Affairs and the rest of the Medical Affairs team to communicate up-to-date scientific/medical information; attend scientific and medical congresses to better understand Medical Affairs’ role at these events

R CO

• Become an integral part of the Multiple Sclerosis Medical Director team in developing and executing medical brand strategies and tactics within the framework of the business unit

Dr. Chavin currently leads a Medical Affairs team at Sanofi Genzyme, in the Multiple Sclerosis Business Unit in Cambridge, MA. Dr. Chavin received his BS in Biology with Honors from Lafayette College, Easton, PA and received his MD degree from Temple University School of Medicine, Philadelphia, PA. Dr. Chavin completed his internship at Penn Presbyterian Medical Center, Philadelphia, PA and completed his Neurology Residency at Thomas Jefferson University Hospital. He also completed his Neuromuscular Medicine Fellowship at Tufts Medical Center, Boston, MA. Prior to joining Genzyme, Dr. Chavin held a faculty appointment as an Associate Professor of Neurology at Tufts Medical Center, Boston, MA where he was the Director of the Multiple Sclerosis Center.

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

US MEDICAL AFFAIRS/MEDICAL SCIENCE LIAISON: RARE DISEASES PROGRAM GOALS

PROGRAM LEAD/PRECEPTOR

To gain a thorough understanding of rare conditions and their treatments while working cross-functionally as an integral member of the Medical Affairs teams. This unique opportunity will prepare the candidates for a field-based Medical Science Liaison position.

Barton Isaac, PharmD Dr. Isaac is a post-doctoral trained pharmacist with over 16 years of Field Medical experience. His first 2 years were with BMS and he then moved to Aventis Pharmaceuticals. The company changed around him, from Aventis to Sanofi-Aventis and now within Sanofi Genzyme; celebrating 15 years this past January 2017. His industry experience has been with various adult medicine disease states: arterial and venous thrombosis, antiplatelet therapy, atrial fibrillation with

PRIMARY OBJECTIVES

• Under the supervision of the US Medical Affairs team, give disease and treatment presentations and provide key messaging to communicate with internal and external stakeholders • Work with the Medical Science Liaison Disease Expert Teams on the development of core clinical materials and assist external venders with the finalization of these projects

• Establish a collaborative relationship with internal colleagues in various departments within Sanofi Genzyme as well as external stakeholders

NS

US Medical Affairs Medical Science Liaison Teams

EL

TI EC

Positions recruiting

1

VE ROTA TI O

Medical Communications/ Publications

S

• Lead projects within US Medical Affairs, including creation of deliverables, congress planning and planning of scientific engagement

E ROTATIO

N

• Attend medical and scientific meetings to ensure an in-depth understanding of cutting-edge information that will help shape the Medical Affairs strategy

R CO

Market Access Competitive Intelligence Patient Advocacy Commercial/Marketing

First-Year Fellow

Second-Year Fellow

Michael Wells, PharmD UNC Eshelman School of Pharmacy

Rebecca Call, PharmD UNC Eshelman School of Pharmacy

Sanofi Genzyme is the global leader in rare diseases and undoubtedly will provide the optimal learning environment for my postgraduate training. Sanofi Genzyme’s unique collaboration with MCPHS University allows Fellows to engage in academic endeavors while simultaneously building working relationships with esteemed faculty within the school. Most importantly, the people that compromise Sanofi Genzyme continuously support my personal and professional development, and ensure my experience during the Fellowship is directly translatable to my future career.

28

I have been greatly honored to work at Sanofi Genzyme for the past year. I truly enjoy the unique nature of my focused program, which allows me to work closely with our two rare disease Medical Science Liaison teams and with other colleagues in US Medical Affairs. My team is incredibly supportive, but also pushes me to try different experiences and lead new projects. I am looking forward to completing more high impact work in my second year!

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

• Prepare for the role of a field-based Medical Science Liaison within US Medical Affairs by completing written and oral Medical Science Liaison certifications

antiarrhythmic agents, diabetes and lipids (including homozygous familial hypercholesterolemia) and most recently, thyroid cancers (differentiated thyroid cancer and medullary thyroid cancer). His varied background and expertise makes him an invaluable mentor for the Fellowship Program.

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

US MEDICAL AFFAIRS/MEDICAL SCIENCE LIAISON: RARE DISEASES PROGRAM GOALS

PROGRAM LEAD/PRECEPTOR

To gain a thorough understanding of rare conditions and their treatments while working cross-functionally as an integral member of the Medical Affairs teams. This unique opportunity will prepare the candidates for a field-based Medical Science Liaison position.

Barton Isaac, PharmD Dr. Isaac is a post-doctoral trained pharmacist with over 16 years of Field Medical experience. His first 2 years were with BMS and he then moved to Aventis Pharmaceuticals. The company changed around him, from Aventis to Sanofi-Aventis and now within Sanofi Genzyme; celebrating 15 years this past January 2017. His industry experience has been with various adult medicine disease states: arterial and venous thrombosis, antiplatelet therapy, atrial fibrillation with

PRIMARY OBJECTIVES

• Under the supervision of the US Medical Affairs team, give disease and treatment presentations and provide key messaging to communicate with internal and external stakeholders • Work with the Medical Science Liaison Disease Expert Teams on the development of core clinical materials and assist external venders with the finalization of these projects

• Establish a collaborative relationship with internal colleagues in various departments within Sanofi Genzyme as well as external stakeholders

NS

US Medical Affairs Medical Science Liaison Teams

EL

TI EC

Positions recruiting

1

VE ROTA TI O

Medical Communications/ Publications

S

• Lead projects within US Medical Affairs, including creation of deliverables, congress planning and planning of scientific engagement

E ROTATIO

N

• Attend medical and scientific meetings to ensure an in-depth understanding of cutting-edge information that will help shape the Medical Affairs strategy

R CO

Market Access Competitive Intelligence Patient Advocacy Commercial/Marketing

First-Year Fellow

Second-Year Fellow

Michael Wells, PharmD UNC Eshelman School of Pharmacy

Rebecca Call, PharmD UNC Eshelman School of Pharmacy

Sanofi Genzyme is the global leader in rare diseases and undoubtedly will provide the optimal learning environment for my postgraduate training. Sanofi Genzyme’s unique collaboration with MCPHS University allows Fellows to engage in academic endeavors while simultaneously building working relationships with esteemed faculty within the school. Most importantly, the people that compromise Sanofi Genzyme continuously support my personal and professional development, and ensure my experience during the Fellowship is directly translatable to my future career.

28

I have been greatly honored to work at Sanofi Genzyme for the past year. I truly enjoy the unique nature of my focused program, which allows me to work closely with our two rare disease Medical Science Liaison teams and with other colleagues in US Medical Affairs. My team is incredibly supportive, but also pushes me to try different experiences and lead new projects. I am looking forward to completing more high impact work in my second year!

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

• Prepare for the role of a field-based Medical Science Liaison within US Medical Affairs by completing written and oral Medical Science Liaison certifications

antiarrhythmic agents, diabetes and lipids (including homozygous familial hypercholesterolemia) and most recently, thyroid cancers (differentiated thyroid cancer and medullary thyroid cancer). His varied background and expertise makes him an invaluable mentor for the Fellowship Program.

38

40


US MEDICAL AFFAIRS/MEDICAL SCIENCE LIAISON: MULTIPLE SCLEROSIS

4

The U.S. Medical Affairs/ Medical Science Liaison Fellow will integrate into all aspects of the field medical role to develop key competencies and skills in learning: principles of the Medical Science Liaison role, effective scientific communication, and cross-functional collaboration with other key functions within both Medical Affairs and additional cross-functional areas. • Training and development in core competencies of the Medical Science Liaison role, leadership, and professional development including the noon conference series and Fellow development opportunities.

F IE L

D WOR

Field Intensive - Medical Science Liaison Experience

14

16

18

20

22

24

26

28

30

32

34

36

Dr. Farnett is currently a Regional Director for the South Multiple Sclerosis Medical Science Liaison team at Sanofi Genzyme. She received her baccalaureate degree in Pharmacy from the University at Buffalo, NY, and her PharmD degree from the University of Texas, Austin. She subsequently did an Ambulatory Care Residency and Fellowship at the Audie Murphy VA Hospital in San Antonio, Texas, with a focus on cardiology and neurology. She then held various academic and clinical positions at Oregon State

University, Corvallis and the University of Texas, as well as a position in a private medical office. Dr. Farnett has conducted several clinical research trials, and has had numerous publications in peer-reviewed journals such as JAMA, Annals of Internal Medicine, Archives of Internal Medicine, and Pharmacotherapy. She joined industry in 2004 in the cardiovascular division of Aventis and moved to Genzyme in 2011 to work in the multiple sclerosis arena with the exciting development of new compounds.

Positions recruiting

1

Longitudinal Field Experience Medical Managed Care Experience

TI EC

VE ROTA TI O

S

Competitive/Market Intelligence

N

EL

New Product Planning

IO

N

I

Medical Publications Scientific Communications Medical Information Services Medical Director Rotation

Second-Year Fellow

Brandon Andereck, PharmD St. Louis College of Pharmacy

Jennifer Cardone, PharmD Northeastern University

I chose to pursue a Fellowship at Sanofi Genzyme because of the opportunities to not only specialize in my function, but explore a wide range of opportunities in other functions within the industry itself. Benjamin Franklin said, ‘tell me and I forget, teach me and I may remember, involve me and I learn’ and this is clearly the philosophy at Sanofi Genzyme; the teams are professional, knowledgeable, and extremely welcoming.

-

SE ROTAT

S

N

U HO

Marketing/Commercial Operations

First-Year Fellow

Over the past year, I have been actively involved with several teams, including working with Medical Science Liaison, Medical Information, Medical Managed Care, and several Medical Director teams. My experiences have extended outside of medical functions to include rotations with competitive intelligence and public affairs and advocacy. I look forward to further developing my skills in the field and building upon my experiences to date.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

Health Outcomes Research (HEOR)

• Drive strategic projects important to the team function such as congress planning, work team projects and other projects as assigned.

30

12

K

• Work with Medical Affairs teams to help shape medical communication strategy and development/ approval of core medical material and field tactics, and attend medical/scientific meetings to understand cutting-edge information.

• Collaborate between US Medical Payer Access position and the Medical Science Liaison position to gain extensive exposure to these two functional areas.

10

Lisa Farnett, PharmD

PRIMARY OBJECTIVES

• Work in the field, under the direction of a Medical Science Liaison mentor, to gain skills in effective communication of scientific data, applying the medical strategy and developing peer to peer scientific partnerships with practitioners in multiple sclerosis.

8

PROGRAM LEAD/PRECEPTOR

PROGRAM GOALS

• Participate in the New Hire Training and complete MSL certification.

6

38

40


US MEDICAL AFFAIRS/MEDICAL SCIENCE LIAISON: MULTIPLE SCLEROSIS

4

The U.S. Medical Affairs/ Medical Science Liaison Fellow will integrate into all aspects of the field medical role to develop key competencies and skills in learning: principles of the Medical Science Liaison role, effective scientific communication, and cross-functional collaboration with other key functions within both Medical Affairs and additional cross-functional areas. • Training and development in core competencies of the Medical Science Liaison role, leadership, and professional development including the noon conference series and Fellow development opportunities.

F IE L

D WOR

Field Intensive - Medical Science Liaison Experience

14

16

18

20

22

24

26

28

30

32

34

36

Dr. Farnett is currently a Regional Director for the South Multiple Sclerosis Medical Science Liaison team at Sanofi Genzyme. She received her baccalaureate degree in Pharmacy from the University at Buffalo, NY, and her PharmD degree from the University of Texas, Austin. She subsequently did an Ambulatory Care Residency and Fellowship at the Audie Murphy VA Hospital in San Antonio, Texas, with a focus on cardiology and neurology. She then held various academic and clinical positions at Oregon State

University, Corvallis and the University of Texas, as well as a position in a private medical office. Dr. Farnett has conducted several clinical research trials, and has had numerous publications in peer-reviewed journals such as JAMA, Annals of Internal Medicine, Archives of Internal Medicine, and Pharmacotherapy. She joined industry in 2004 in the cardiovascular division of Aventis and moved to Genzyme in 2011 to work in the multiple sclerosis arena with the exciting development of new compounds.

Positions recruiting

1

Longitudinal Field Experience Medical Managed Care Experience

TI EC

VE ROTA TI O

S

Competitive/Market Intelligence

N

EL

New Product Planning

IO

N

I

Medical Publications Scientific Communications Medical Information Services Medical Director Rotation

Second-Year Fellow

Brandon Andereck, PharmD St. Louis College of Pharmacy

Jennifer Cardone, PharmD Northeastern University

I chose to pursue a Fellowship at Sanofi Genzyme because of the opportunities to not only specialize in my function, but explore a wide range of opportunities in other functions within the industry itself. Benjamin Franklin said, ‘tell me and I forget, teach me and I may remember, involve me and I learn’ and this is clearly the philosophy at Sanofi Genzyme; the teams are professional, knowledgeable, and extremely welcoming.

-

SE ROTAT

S

N

U HO

Marketing/Commercial Operations

First-Year Fellow

Over the past year, I have been actively involved with several teams, including working with Medical Science Liaison, Medical Information, Medical Managed Care, and several Medical Director teams. My experiences have extended outside of medical functions to include rotations with competitive intelligence and public affairs and advocacy. I look forward to further developing my skills in the field and building upon my experiences to date.

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

Health Outcomes Research (HEOR)

• Drive strategic projects important to the team function such as congress planning, work team projects and other projects as assigned.

30

12

K

• Work with Medical Affairs teams to help shape medical communication strategy and development/ approval of core medical material and field tactics, and attend medical/scientific meetings to understand cutting-edge information.

• Collaborate between US Medical Payer Access position and the Medical Science Liaison position to gain extensive exposure to these two functional areas.

10

Lisa Farnett, PharmD

PRIMARY OBJECTIVES

• Work in the field, under the direction of a Medical Science Liaison mentor, to gain skills in effective communication of scientific data, applying the medical strategy and developing peer to peer scientific partnerships with practitioners in multiple sclerosis.

8

PROGRAM LEAD/PRECEPTOR

PROGRAM GOALS

• Participate in the New Hire Training and complete MSL certification.

6

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

US MEDICAL MANAGED CARE PROGRAM GOALS

PROGRAM LEADS/PRECEPTORS

To gain advanced experience in field medical interactions with US payers and other health-care delivery models including PBMs, HMO/PPO, ACO/IDN, Medicare, Medicaid, and at-risk physician groups. This experience will provide exposure to numerous medical and commercial functions within Sanofi Genzyme in the specialty pharmaceutical market and prepare the candidate for a field-based medical managed care or outcome liaison role.

• Work closely with the Medical Managed Care team to provide comprehensive medical education and health outcomes solutions to key market decision/ policy-makers.

• Work with the Medical Managed Care and Health Economic & Outcomes Research teams to design and execute Health Economic & Outcomes Research strategies and projects with payers and research organizations. • Gain an understanding of the various payer models and translating clinical and health economics messaging to deliver a targeted value proposition to a specific customer. 32

Medical Managed Care (HQ and Field Medical Relations)

Positions recruiting

Health Economic & Outcomes Research

1

Medical Science Liaison Healthcare Policy Value & Access (Commercial)

EL

TI EC

VE ROTA TI O

Global Scientific Communication

Dr. Stam started his industry career at Sanofi in 1999 working in several field medical roles, including Medical Science Liaison and Regional Director. Prior to that, Dr. Stam was an Assistant Professor of Pharmacy Practice at the St. Louis College of Pharmacy and maintained several pharmacy managed clinics in a VA ambulatory care setting. Dr. Stam maintains an adjunct clinical faculty appointment at the St. Louis College of Pharmacy.

S

• Train and support cross-functional colleagues on health-economic data communication and identify potential cross-functional collaborations between the Medical Managed Care and Medical Science Liaison teams.

NS

N

• Support the Medical Managed Care team in tool development and in customer engagements in the field and provide insights to internal medical teams on key evidence gaps relevant to specific accounts.

E ROTATIO

Medical Information Services Global Pharmacovigilance & Epidemiology Global Commercial Strategy Medical Affairs (MSOI) Regulatory Affairs

Dr. Sanchirico is an immunologist who has worked in various roles in Sanofi Genzyme Medical Affairs since 2005 and is currently a Director with the Genzyme Medical Managed Care team for Multiple Sclerosis, Oncology and Immunology. Prior to joining Sanofi, Dr. Sanchirico was an Associate Professor at University of Massachusetts Medical School, Worcester, MA and Instructor of Medicine at Harvard Medical School, Boston, MA. Dr. Sanchirico received her Bachelor’s degree in biochemistry at Ithaca College, NY, and her PhD from the University of Massachusetts, Amherst, MA and specialty trained in Immunology as a postdoctoral Fellow at Harvard Medical School/Dana Farber Cancer Institute.

First-Year Fellow

Second-Year Fellow

Alvin Ong, PharmD UNC Eshelman School of Pharmacy

Paul Isikwe, PharmD Touro College of Pharmacy

Given my interest in a field-based position focused on payers, I truly could not have found a better Fellowship more suited to my career goals. I am extremely fortunate to be a part of the US Medical Managed Care team where I will receive outstanding tutelage from highly experienced professionals who are committed to my professional and personal development. The experiences I will gain, spanning from medical strategy and research to commercial, will undoubtedly separate me as a quality candidate as I pursue a career in this space after my Fellowship.

Sanofi Genzyme is an exciting company to be a part of. In just 1 year I have gained more experiences than I can imagine. The flexibility and versatility of this Fellowship are what drew me to it and it has lived up to every expectation! I owe this to the skilled professionals with whom I work alongside. A Medical Managed Care Fellow will embrace the true cross-functional environment of the biopharmaceutical industry.

• Collaborate between the Medical Science Liaison position and US Medical Managed Care position (focused in Multiple Sclerosis, Oncology, and Immunology) gaining a balanced, yet extensive amount of exposure to our field medical areas.

R CO

Dr. Stam is currently the Senior Director, Head of Medical Managed Care for Multiple Sclerosis, Immunology, and Oncology within Sanofi Genzyme North America Medical Affairs. Dr. Stam earned his BS and PharmD degrees from St. Louis College of Pharmacy, St. Louis, MO and completed an ASHPaccredited primary care specialty Residency at the John Cochran VA Medical Center/St. Louis College of Pharmacy, St. Louis, MO.

Marie Sanchirico, PhD

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

PRIMARY OBJECTIVES

Darren Stam, PharmD

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

US MEDICAL MANAGED CARE PROGRAM GOALS

PROGRAM LEADS/PRECEPTORS

To gain advanced experience in field medical interactions with US payers and other health-care delivery models including PBMs, HMO/PPO, ACO/IDN, Medicare, Medicaid, and at-risk physician groups. This experience will provide exposure to numerous medical and commercial functions within Sanofi Genzyme in the specialty pharmaceutical market and prepare the candidate for a field-based medical managed care or outcome liaison role.

• Work closely with the Medical Managed Care team to provide comprehensive medical education and health outcomes solutions to key market decision/ policy-makers.

• Work with the Medical Managed Care and Health Economic & Outcomes Research teams to design and execute Health Economic & Outcomes Research strategies and projects with payers and research organizations. • Gain an understanding of the various payer models and translating clinical and health economics messaging to deliver a targeted value proposition to a specific customer. 32

Medical Managed Care (HQ and Field Medical Relations)

Positions recruiting

Health Economic & Outcomes Research

1

Medical Science Liaison Healthcare Policy Value & Access (Commercial)

EL

TI EC

VE ROTA TI O

Global Scientific Communication

Dr. Stam started his industry career at Sanofi in 1999 working in several field medical roles, including Medical Science Liaison and Regional Director. Prior to that, Dr. Stam was an Assistant Professor of Pharmacy Practice at the St. Louis College of Pharmacy and maintained several pharmacy managed clinics in a VA ambulatory care setting. Dr. Stam maintains an adjunct clinical faculty appointment at the St. Louis College of Pharmacy.

S

• Train and support cross-functional colleagues on health-economic data communication and identify potential cross-functional collaborations between the Medical Managed Care and Medical Science Liaison teams.

NS

N

• Support the Medical Managed Care team in tool development and in customer engagements in the field and provide insights to internal medical teams on key evidence gaps relevant to specific accounts.

E ROTATIO

Medical Information Services Global Pharmacovigilance & Epidemiology Global Commercial Strategy Medical Affairs (MSOI) Regulatory Affairs

Dr. Sanchirico is an immunologist who has worked in various roles in Sanofi Genzyme Medical Affairs since 2005 and is currently a Director with the Genzyme Medical Managed Care team for Multiple Sclerosis, Oncology and Immunology. Prior to joining Sanofi, Dr. Sanchirico was an Associate Professor at University of Massachusetts Medical School, Worcester, MA and Instructor of Medicine at Harvard Medical School, Boston, MA. Dr. Sanchirico received her Bachelor’s degree in biochemistry at Ithaca College, NY, and her PhD from the University of Massachusetts, Amherst, MA and specialty trained in Immunology as a postdoctoral Fellow at Harvard Medical School/Dana Farber Cancer Institute.

First-Year Fellow

Second-Year Fellow

Alvin Ong, PharmD UNC Eshelman School of Pharmacy

Paul Isikwe, PharmD Touro College of Pharmacy

Given my interest in a field-based position focused on payers, I truly could not have found a better Fellowship more suited to my career goals. I am extremely fortunate to be a part of the US Medical Managed Care team where I will receive outstanding tutelage from highly experienced professionals who are committed to my professional and personal development. The experiences I will gain, spanning from medical strategy and research to commercial, will undoubtedly separate me as a quality candidate as I pursue a career in this space after my Fellowship.

Sanofi Genzyme is an exciting company to be a part of. In just 1 year I have gained more experiences than I can imagine. The flexibility and versatility of this Fellowship are what drew me to it and it has lived up to every expectation! I owe this to the skilled professionals with whom I work alongside. A Medical Managed Care Fellow will embrace the true cross-functional environment of the biopharmaceutical industry.

• Collaborate between the Medical Science Liaison position and US Medical Managed Care position (focused in Multiple Sclerosis, Oncology, and Immunology) gaining a balanced, yet extensive amount of exposure to our field medical areas.

R CO

Dr. Stam is currently the Senior Director, Head of Medical Managed Care for Multiple Sclerosis, Immunology, and Oncology within Sanofi Genzyme North America Medical Affairs. Dr. Stam earned his BS and PharmD degrees from St. Louis College of Pharmacy, St. Louis, MO and completed an ASHPaccredited primary care specialty Residency at the John Cochran VA Medical Center/St. Louis College of Pharmacy, St. Louis, MO.

Marie Sanchirico, PhD

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

PRIMARY OBJECTIVES

Darren Stam, PharmD

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

GLOBAL REGULATORY AFFAIRS PROGRAM GOALS

PROGRAM LEAD/PRECEPTOR

To gain hands-on experience across a number of specialties within the Global Regulatory Affairs department and to develop a well-rounded understanding of the regulatory functions and drug development process from early stage to post-marketing.

Ms. Clarke is currently the Lead of Regulatory Training and Development within Global Regulatory Affairs, with a focus on organizational change management. Ms. Clarke has over 25 years of experience in both the Pharmaceutical and Biopharmaceutical industry, and has had responsibilities for global regulatory product strategy for both investigational and globally approved products in the areas of vaccines, cell therapy for oncology, ophthalmic products, renal, rare

PRIMARY OBJECTIVES

• Partner with Medical, Legal, Marketing, and Safety in delivering products for diseases globally • Gain experience in the review and approval of promotional materials, including effective feedback skills • Opportunity to engage with global colleagues and learn country-/region-specific regulatory processes • Develop strong communication and project management skills

R CO

E ROTATIO

NS

The core rotation will be in global product strategy, with additional rotations available in:

Advertising and Promotion Chemistry, Manufacturing, and Controls & Devices Labeling Regulatory Science & Policy Positions recruiting

2

Second-Year Fellow

Second-Year Fellow

Bridget Cloonan, PharmD, RPh MCPHS University – Boston

Kishan Mistry, PharmD Northeastern University

Over the past year, my Fellowship has provided me unparalleled opportunities to serve as an integral member of the Global Regulatory Affairs team. I have served as a strategic partner in developing creative regulatory solutions for multiple high-profile projects within the organization. I have learned from incredible mentors devoted to my development into a strong Regulatory Affairs professional. I attribute my personal and professional growth to this Fellowship Program, which is dedicated to providing a challenging yet supportive environment to provide the Fellows with the skills necessary for success within the biopharmaceutical industry.

34

disease, neurology, and endocrine. Ms. Clarke earned a BS in Biology from the University of Massachusetts, Boston and an MS degree in Drug Regulatory Affairs and Health Policy at MCPHS University in Boston, MA.

Since the start of my Fellowship, I continue to be provided with unique opportunities, diverse resources, and excellent mentorship within the Regulatory Affairs department and the company as a whole which are fundamental towards gaining the knowledge to become a strong Regulatory Affairs professional. My experience working on crucial projects at various stages of the drug development process and directly collaborating with other company departments and global health authorities prepares me to serve as an integral member of the Global Regulatory Affairs team and develop myself both personally and professionally.

• Develop regulatory strategic skills while contributing to global pre- and post-approval planning and submissions

Mary Beth Clarke, MS

First-Year Fellow

First-Year Fellow

Afeefa Bhatti, PharmD MCPHS University – Worcester

Paulius Petrosius, PharmD University of Illinois at Chicago

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

GLOBAL REGULATORY AFFAIRS PROGRAM GOALS

PROGRAM LEAD/PRECEPTOR

To gain hands-on experience across a number of specialties within the Global Regulatory Affairs department and to develop a well-rounded understanding of the regulatory functions and drug development process from early stage to post-marketing.

Ms. Clarke is currently the Lead of Regulatory Training and Development within Global Regulatory Affairs, with a focus on organizational change management. Ms. Clarke has over 25 years of experience in both the Pharmaceutical and Biopharmaceutical industry, and has had responsibilities for global regulatory product strategy for both investigational and globally approved products in the areas of vaccines, cell therapy for oncology, ophthalmic products, renal, rare

PRIMARY OBJECTIVES

• Partner with Medical, Legal, Marketing, and Safety in delivering products for diseases globally • Gain experience in the review and approval of promotional materials, including effective feedback skills • Opportunity to engage with global colleagues and learn country-/region-specific regulatory processes • Develop strong communication and project management skills

R CO

E ROTATIO

NS

The core rotation will be in global product strategy, with additional rotations available in:

Advertising and Promotion Chemistry, Manufacturing, and Controls & Devices Labeling Regulatory Science & Policy Positions recruiting

2

Second-Year Fellow

Second-Year Fellow

Bridget Cloonan, PharmD, RPh MCPHS University – Boston

Kishan Mistry, PharmD Northeastern University

Over the past year, my Fellowship has provided me unparalleled opportunities to serve as an integral member of the Global Regulatory Affairs team. I have served as a strategic partner in developing creative regulatory solutions for multiple high-profile projects within the organization. I have learned from incredible mentors devoted to my development into a strong Regulatory Affairs professional. I attribute my personal and professional growth to this Fellowship Program, which is dedicated to providing a challenging yet supportive environment to provide the Fellows with the skills necessary for success within the biopharmaceutical industry.

34

disease, neurology, and endocrine. Ms. Clarke earned a BS in Biology from the University of Massachusetts, Boston and an MS degree in Drug Regulatory Affairs and Health Policy at MCPHS University in Boston, MA.

Since the start of my Fellowship, I continue to be provided with unique opportunities, diverse resources, and excellent mentorship within the Regulatory Affairs department and the company as a whole which are fundamental towards gaining the knowledge to become a strong Regulatory Affairs professional. My experience working on crucial projects at various stages of the drug development process and directly collaborating with other company departments and global health authorities prepares me to serve as an integral member of the Global Regulatory Affairs team and develop myself both personally and professionally.

• Develop regulatory strategic skills while contributing to global pre- and post-approval planning and submissions

Mary Beth Clarke, MS

First-Year Fellow

First-Year Fellow

Afeefa Bhatti, PharmD MCPHS University – Worcester

Paulius Petrosius, PharmD University of Illinois at Chicago

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


GLOBAL REGULATORY AFFAIRS: CHEMISTRY, MANUFACTURING, AND CONTROLS & DEVICES PROGRAM GOALS

PRIMARY OBJECTIVES

• Opportunity to tailor the program to your unique interests and professional development needs • Explore the Global Regulatory landscape for Medical Devices through a potential 6-month rotation • Exposure to the entire manufacturing process from development through post-marketing for both Biologics and Medical Devices

6

8

10

12

14

16

18

20

22

Positions recruiting

1

Maria O’Connell, MLIS, RAC

26

28

30

32

34

36

Ms. O’Connell is currently a Manager within Global Regulatory Affairs: Chemistry, Manufacturing, and Controls Biologics and has over 14 years of experience in the pharmaceutical industry. Her career started as a Research Librarian at Wyeth, and progressed to the Regulatory Operations group at Sanofi Genzyme. She moved within Regulatory to various functions, including Compliance and Chemistry, Manufacturing, and Controls. Ms. O’Connell earned a Bachelor’s degree in Planetary Geology from Mount Holyoke College, South Hadley, MA and a Master’s degree in Library and Information Science from Simmons College, Boston, MA. She is currently enrolled in the Regulatory Science program at the University of California, Los Angeles, CA for another Master’s degree.

Elizabete Andre, MS Ms. Andre is currently a Senior Associate within Global Regulatory Affairs: Chemistry, Manufacturing, and Controls Biologics with over 10 years of experience within the pharmaceutical industry. She obtained a Master’s degree from Northeastern University, Boston, MA focusing on Domestic and International Regulatory Affairs. While her career started out with a focus on small molecule research and development, she transitioned from the laboratory into Regulatory Affairs Chemistry, Manufacturing, and Controls. Since then, Elizabete has worked on a number of Biological products ranging from development to post-market approval and ensuring their regulatory success both domestically and internationally.

• Opportunity for direct agency interactions with both US and non-US health authorities • Gain an understanding of country-specific regulations by interacting with our affiliates worldwide

36

24

PROGRAM LEADS/PRECEPTORS

To gain a thorough understanding of the regulatory functions of the Global Regulatory Affairs Chemistry, Manufacturing, and Controls department and build a strong foundation in the drug/device development process from early stage to post-marketing with a focus in Biologics Chemistry, Manufacturing, and Controls. • Focus on Biologic Products in various therapeutic areas including cardiovascular, immunology, multiple sclerosis, oncology, and diabetes, many of which are orphan drugs for rare diseases

4

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


GLOBAL REGULATORY AFFAIRS: CHEMISTRY, MANUFACTURING, AND CONTROLS & DEVICES PROGRAM GOALS

PRIMARY OBJECTIVES

• Opportunity to tailor the program to your unique interests and professional development needs • Explore the Global Regulatory landscape for Medical Devices through a potential 6-month rotation • Exposure to the entire manufacturing process from development through post-marketing for both Biologics and Medical Devices

6

8

10

12

14

16

18

20

22

Positions recruiting

1

Maria O’Connell, MLIS, RAC

26

28

30

32

34

36

Ms. O’Connell is currently a Manager within Global Regulatory Affairs: Chemistry, Manufacturing, and Controls Biologics and has over 14 years of experience in the pharmaceutical industry. Her career started as a Research Librarian at Wyeth, and progressed to the Regulatory Operations group at Sanofi Genzyme. She moved within Regulatory to various functions, including Compliance and Chemistry, Manufacturing, and Controls. Ms. O’Connell earned a Bachelor’s degree in Planetary Geology from Mount Holyoke College, South Hadley, MA and a Master’s degree in Library and Information Science from Simmons College, Boston, MA. She is currently enrolled in the Regulatory Science program at the University of California, Los Angeles, CA for another Master’s degree.

Elizabete Andre, MS Ms. Andre is currently a Senior Associate within Global Regulatory Affairs: Chemistry, Manufacturing, and Controls Biologics with over 10 years of experience within the pharmaceutical industry. She obtained a Master’s degree from Northeastern University, Boston, MA focusing on Domestic and International Regulatory Affairs. While her career started out with a focus on small molecule research and development, she transitioned from the laboratory into Regulatory Affairs Chemistry, Manufacturing, and Controls. Since then, Elizabete has worked on a number of Biological products ranging from development to post-market approval and ensuring their regulatory success both domestically and internationally.

• Opportunity for direct agency interactions with both US and non-US health authorities • Gain an understanding of country-specific regulations by interacting with our affiliates worldwide

36

24

PROGRAM LEADS/PRECEPTORS

To gain a thorough understanding of the regulatory functions of the Global Regulatory Affairs Chemistry, Manufacturing, and Controls department and build a strong foundation in the drug/device development process from early stage to post-marketing with a focus in Biologics Chemistry, Manufacturing, and Controls. • Focus on Biologic Products in various therapeutic areas including cardiovascular, immunology, multiple sclerosis, oncology, and diabetes, many of which are orphan drugs for rare diseases

4

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


4

MCPHS UNIVERSITY

As a private institution with a history of specialization in the health sciences, MCPHS University offers programs that embody scholarship, professional service, and community outreach. Through MCPHS University, the Fellow will have the opportunity to gain teaching and research experience in an academic setting. MCPHS University faculty and company Program Leaders mentor Fellows according to their scholarly and professional interests throughout the 2-year program.

MCPHS University Fellowship Director Dr. Mistry is an Associate Professor of Pharmacy Practice and has been with MCPHS University since 2006. Dr. Mistry earned her PharmD at the Albany College of Pharmacy and Health Sciences Albany, NY and completed a PGY1 Community Practice Residency with Walgreens and MCPHS University. In 2015, Dr. Mistry took over as Director of

the MCPHS Biopharmaceutical Industry Fellowship Program. She works directly with leaders in the area to continue to foster growth and development of the postgraduate program, and to assist the Fellows in attaining positions within the pharmaceutical industry. She also continues to teach and conduct scholarly work at MCPHS University, nationally trains pharmacists and student pharmacists on immunizations, and is actively involved in her state and national pharmacy organizations.

MCPHS University Fellowship Preceptors Samantha Nganju, BA Program Administrator

Colleen Massey, MS Director of Operations of Pharmacy Practice

Helen Pervanas, PharmD Associate Professor of Pharmacy Practice

Amanda Morrill, PharmD, BCPS Assistant Professor of Pharmacy Practice

Maryann Cooper, PharmD, BCOP Associate Professor of Pharmacy Practice

Matthew Silva, PharmD, BCPS Professor of Pharmacy Practice

Evan Horton, PharmD Associate Professor of Pharmacy Practice

Trisha LaPointe, PharmD, BCBS, FASHP Associate Professor of Pharmacy Practice

38

Donna Bartlett, PharmD, CGP Associate Professor of Pharmacy Practice, Clinical Pharmacist, and Pharmacy Outreach Program

Stephanie L. Conway, PharmD Assistant Professor of Pharmacy Practice

Steven J. Crosby, MA, BSP Assistant Professor of Pharmacy Practice

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

FELLOWSHIP ALUMNI

MCPHS University provides an academic environment to guide and support Fellows toward a successful career in the biopharmaceutical industry.

Amee Mistry, PharmD

6

Ricky Thumar, PharmD Assistant Professor of Pharmacy Practice and Physician Assistant Studies Erika Felix-Getzik, PharmD Associate Professor of Pharmacy Practice

David Schnee, PharmD, BCACP Associate Professor of Pharmacy Practice

Name

Alma Mater

Fellowship Completed

Fellowship Graduation Year

Angela Kang

Rutgers University

Clinical Pharmacy

2005

Angeliki Karapanos

University of Connecticut

Clinical Pharmacy

2006

Marisol Kcomt

University of Michigan

Clinical Pharmacy

2007

Dan Giang

Creighton University

Clinical Pharmacy

2008

Paul Larochelle

MCPHS University

Clinical Pharmacy

2009

Lisa Pelunis-Messier

MCPHS University

Clinical Pharmacy

2010

SaraBeth Hahn

Northeastern University

Regulatory Affairs

2011

Sheryl Selvey

Butler University

Global Medical Affairs: Oncology

2011

Aimee Nilsen

MCPHS University

Global Pharmacovigilance & Epidemiology

2011

Deanna Scinto

St. John’s University

Clinical Research

2011

Kelsey White

Northeastern University

Clinical Research

2012

Eleanor Yu

MCPHS University

Regulatory Affairs

2012

Samantha Llanos

Rutgers University

Global Pharmacovigilance & Epidemiology

2012

Mugdha Sitole

Albany College of Pharmacy and Health Sciences

Clinical Research

2013

Kinjal Patel

Philadelphia College of Pharmacy, University of the Sciences

Global Pharmacovigilance & Epidemiology

2013

Candra J. Williams

Florida Agriculture and Mechanical University

Regulatory Affairs

2014

Swati Shah

Rutgers University

Clinical Supplies/Investigational Products

2014

Kiki Patel

Northeastern University

Global Medical Affairs: Oncology

2014

Eddie Han

Northeastern University

Clinical Supplies/Investigational Products

2014

Kelly Hageman

University of Rhode Island

Global Medical Affairs: Oncology

2014

Venitia Bernard

Florida Agriculture and Mechanical University

Regulatory Affairs

2014

Shushama Alam

Philadelphia College of Pharmacy, University of the Sciences

Global Medical Affairs: Rare Diseases

2014

Ashlee Vilardi

Albany College of Pharmacy and Health Sciences

Global Pharmacovigilance & Epidemiology

2015

Rebecca Pleat

MCPHS University

Global Medical Affairs: Rare Diseases

2015

Shane McGann

Albany College of Pharmacy and Health Sciences

Regulatory Affairs

2015

Sujin Key

Purdue University

Clinical Supplies

2015

Christina Zhao

University of Michigan

Global Medical Affairs: Oncology

2015

Jessica Bannan

Albany College of Pharmacy and Health Sciences

Regulatory Affairs

2015

Jennifer Pisani

University of Michigan

Regulatory Affairs

2016

Kate Szymaniak

MCPHS University

Global Pharmacovigilance & Epidemiology

2016

Amy Monpara

University of Pittsburgh

Global Medical Affairs: Oncology

2016

Angela Lye

Philadelphia College of Pharmacy, University of the Sciences

Clinical Documentation

2016

Kenneth Liu

Rutgers University

Medical Science Liaison: Multiple Sclerosis

2016

Ting Lin

Northeastern University

Regulatory Affairs

2016

Carrie Cammarano

MCPHS University

Clinical Supplies

2016

Chelsea Binkowski

Northeastern University

Global Medical Affairs: Oncology

2016

Palni Patel

MCPHS University

Global Pharmacovigilance & Epidemiology

2017

Christy Fang

MCPHS University

Regulatory Affairs

2017

Sarah Stelzleni

Purdue University

Regulatory Affairs

2017

Nate Thibault

MCPHS University

Global Medical Affairs:Rare Diseases

2017

Lucie Vu

University of Southern California

Global Medical Affairs: Rare Diseases

2017

Ahmad Khan

Albany College of Pharmacy and Health Sciences

US Medical Affairs/Medical Science Liaison: Multiple Sclerosis

2017

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


4

MCPHS UNIVERSITY

As a private institution with a history of specialization in the health sciences, MCPHS University offers programs that embody scholarship, professional service, and community outreach. Through MCPHS University, the Fellow will have the opportunity to gain teaching and research experience in an academic setting. MCPHS University faculty and company Program Leaders mentor Fellows according to their scholarly and professional interests throughout the 2-year program.

MCPHS University Fellowship Director Dr. Mistry is an Associate Professor of Pharmacy Practice and has been with MCPHS University since 2006. Dr. Mistry earned her PharmD at the Albany College of Pharmacy and Health Sciences Albany, NY and completed a PGY1 Community Practice Residency with Walgreens and MCPHS University. In 2015, Dr. Mistry took over as Director of

the MCPHS Biopharmaceutical Industry Fellowship Program. She works directly with leaders in the area to continue to foster growth and development of the postgraduate program, and to assist the Fellows in attaining positions within the pharmaceutical industry. She also continues to teach and conduct scholarly work at MCPHS University, nationally trains pharmacists and student pharmacists on immunizations, and is actively involved in her state and national pharmacy organizations.

MCPHS University Fellowship Preceptors Samantha Nganju, BA Program Administrator

Colleen Massey, MS Director of Operations of Pharmacy Practice

Helen Pervanas, PharmD Associate Professor of Pharmacy Practice

Amanda Morrill, PharmD, BCPS Assistant Professor of Pharmacy Practice

Maryann Cooper, PharmD, BCOP Associate Professor of Pharmacy Practice

Matthew Silva, PharmD, BCPS Professor of Pharmacy Practice

Evan Horton, PharmD Associate Professor of Pharmacy Practice

Trisha LaPointe, PharmD, BCBS, FASHP Associate Professor of Pharmacy Practice

38

Donna Bartlett, PharmD, CGP Associate Professor of Pharmacy Practice, Clinical Pharmacist, and Pharmacy Outreach Program

Stephanie L. Conway, PharmD Assistant Professor of Pharmacy Practice

Steven J. Crosby, MA, BSP Assistant Professor of Pharmacy Practice

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

FELLOWSHIP ALUMNI

MCPHS University provides an academic environment to guide and support Fellows toward a successful career in the biopharmaceutical industry.

Amee Mistry, PharmD

6

Ricky Thumar, PharmD Assistant Professor of Pharmacy Practice and Physician Assistant Studies Erika Felix-Getzik, PharmD Associate Professor of Pharmacy Practice

David Schnee, PharmD, BCACP Associate Professor of Pharmacy Practice

Name

Alma Mater

Fellowship Completed

Fellowship Graduation Year

Angela Kang

Rutgers University

Clinical Pharmacy

2005

Angeliki Karapanos

University of Connecticut

Clinical Pharmacy

2006

Marisol Kcomt

University of Michigan

Clinical Pharmacy

2007

Dan Giang

Creighton University

Clinical Pharmacy

2008

Paul Larochelle

MCPHS University

Clinical Pharmacy

2009

Lisa Pelunis-Messier

MCPHS University

Clinical Pharmacy

2010

SaraBeth Hahn

Northeastern University

Regulatory Affairs

2011

Sheryl Selvey

Butler University

Global Medical Affairs: Oncology

2011

Aimee Nilsen

MCPHS University

Global Pharmacovigilance & Epidemiology

2011

Deanna Scinto

St. John’s University

Clinical Research

2011

Kelsey White

Northeastern University

Clinical Research

2012

Eleanor Yu

MCPHS University

Regulatory Affairs

2012

Samantha Llanos

Rutgers University

Global Pharmacovigilance & Epidemiology

2012

Mugdha Sitole

Albany College of Pharmacy and Health Sciences

Clinical Research

2013

Kinjal Patel

Philadelphia College of Pharmacy, University of the Sciences

Global Pharmacovigilance & Epidemiology

2013

Candra J. Williams

Florida Agriculture and Mechanical University

Regulatory Affairs

2014

Swati Shah

Rutgers University

Clinical Supplies/Investigational Products

2014

Kiki Patel

Northeastern University

Global Medical Affairs: Oncology

2014

Eddie Han

Northeastern University

Clinical Supplies/Investigational Products

2014

Kelly Hageman

University of Rhode Island

Global Medical Affairs: Oncology

2014

Venitia Bernard

Florida Agriculture and Mechanical University

Regulatory Affairs

2014

Shushama Alam

Philadelphia College of Pharmacy, University of the Sciences

Global Medical Affairs: Rare Diseases

2014

Ashlee Vilardi

Albany College of Pharmacy and Health Sciences

Global Pharmacovigilance & Epidemiology

2015

Rebecca Pleat

MCPHS University

Global Medical Affairs: Rare Diseases

2015

Shane McGann

Albany College of Pharmacy and Health Sciences

Regulatory Affairs

2015

Sujin Key

Purdue University

Clinical Supplies

2015

Christina Zhao

University of Michigan

Global Medical Affairs: Oncology

2015

Jessica Bannan

Albany College of Pharmacy and Health Sciences

Regulatory Affairs

2015

Jennifer Pisani

University of Michigan

Regulatory Affairs

2016

Kate Szymaniak

MCPHS University

Global Pharmacovigilance & Epidemiology

2016

Amy Monpara

University of Pittsburgh

Global Medical Affairs: Oncology

2016

Angela Lye

Philadelphia College of Pharmacy, University of the Sciences

Clinical Documentation

2016

Kenneth Liu

Rutgers University

Medical Science Liaison: Multiple Sclerosis

2016

Ting Lin

Northeastern University

Regulatory Affairs

2016

Carrie Cammarano

MCPHS University

Clinical Supplies

2016

Chelsea Binkowski

Northeastern University

Global Medical Affairs: Oncology

2016

Palni Patel

MCPHS University

Global Pharmacovigilance & Epidemiology

2017

Christy Fang

MCPHS University

Regulatory Affairs

2017

Sarah Stelzleni

Purdue University

Regulatory Affairs

2017

Nate Thibault

MCPHS University

Global Medical Affairs:Rare Diseases

2017

Lucie Vu

University of Southern California

Global Medical Affairs: Rare Diseases

2017

Ahmad Khan

Albany College of Pharmacy and Health Sciences

US Medical Affairs/Medical Science Liaison: Multiple Sclerosis

2017

BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2017–2018

38

40


4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36

38

APPLICATION PROCESS ELIGIBILITY Fellows will be selected on a nationally competitive basis, with interviews at the American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting. Applicants must have a Doctor of Pharmacy degree from an ACPE-accredited college of pharmacy. Candidates must have strong written and verbal communication skills and an interest in pursuing a career in the biopharmaceutical industry. All candidates must have authorization to work in the United States throughout the duration of the 2-year Fellowship. No visa sponsorship will be provided.

APPLICATION PROCEDURE Participation in the ASHP Midyear Clinical Meeting Personnel Placement Service (PPS) is strongly encouraged. To be scheduled for an interview at the ASHP Clinical Midyear Meeting, applicants must upload the following application materials to the online

portal (https://mcphs.fluidreview.com/) prior to attending the ASHP Clinical Midyear Meeting: • Letter of intent • Curriculum vitae • Unofficial college transcript • Contact information for three references for letters of recommendation The three letters of recommendation will need to be submitted by December 20th, 2017 from the three provided contacts. For more information, please correspond with: Adrienne Aiello, PharmD Fellowship Director Sanofi Genzyme PharmDFellowships@genzyme.com Please visit the MCPHS University Biopharmaceutical Fellowship website for more information: http://www.mcphs.edu/GenzymeFellowships

BIOPHARMACEUTICAL INDUSTRY Fellowship Program MCPHS University & Sanofi Genzyme Please visit the MCPHS University Biopharmaceutical Fellowship website for more information: http://www.mcphs.edu/GenzymeFellowships

SAUS.GZ.17.10.8014

40

MCPHS Biopharmaceutical Industry Fellowship Program — Sanofi Genzyme  
MCPHS Biopharmaceutical Industry Fellowship Program — Sanofi Genzyme